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Résumé 
La dérégulation de l’expression génétique est une base pathophysiologique de 
plusieurs maladies. On a utilisé le locus du gène β-globine humain comme modèle pour 
élucider le mécanisme de régulation de la transcription génétique et évaluer son expression 
génétique durant l’érythropoïèse. La famille des protéines ‘E’ est composée de facteurs de 
transcription qui possèdent plusieurs sites de liaison au sein de locus du gène β-globine, 
suggérant leur rôle potentiel dans la régulation de l’expression de ces gènes. Nous avons 
montré que les facteurs HEB, E2A et ETO2 interagissent d’une manière significative avec 
la région contrôle du Locus (LCR) et avec les promoteurs des gènes de la famille β-globine. 
Le recrutement de ces facteurs au locus est modifié lors de l’érythropoïèse dans les cellules 
souches hematopoitiques et les cellules erythroides de souris transgéniques pour le locus de 
la β-globine humain, ainsi que dans les cellules progénitrices hématopoïétiques humaines. 
De plus par cette étude, nous démontrons pour la première fois que le gène β-globine 
humain est dans une chromatine active et qu’il interagit avec des facteurs de transcriptions 
de type suppresseurs dans les cellules progénitrices lymphoïdes (voie de différentiation 
alternative). Cette étude a aussi été faite dans des souris ayant une génétique mutante 
caractérisée par l’absence des facteurs de transcription E2A ou HEB. 
Mots-clés: Expression, Facteur de Transcription, Génétique, Gène, Hématopoïèse, Lignée 
Spécification 
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Abstract 
Aberrant gene expression is an underlying pathophysiology in many disease 
conditions. Lineage-specification and -commitment is tightly dependent on lineage-specific 
transcription factors to regulate the expression of target genes. Using human β-globin locus 
as a model, we investigated how the transcriptional machinery is set and regulated during 
erythropoiesis and how it impacts globally on gene expression. Class I bHLH proteins are 
important transcription factors whose binding sites are frequently clustered throughout the 
β-globin gene locus, suggesting their role in globin gene regulation. We showed that, in 
hematopoietic progenitor (HPC) and erythroid cells (EryC) of the transgenic mouse for 
human β-globin locus and human HPC cells (CD34+); HEB, E2A and ETO-2 significantly 
interact with locus control region (LCR) and promoters of globin genes, and their relative 
ratio is altered during erythropoiesis. For the first time, we found that in other 
hematopoietic lineages, human β-globin locus is in active chromatin and interacts with 
transcription factors involved in repression. Strikingly and consistent with the expression of 
globin genes, we characterized transcription factors involved in open chromatin 
configuration and basal level of globin gene expression in lymphoid progenitor cells. 
Further, with the genetic power of E2A and HEB knockout mice, our findings were 
clarified in mutant backgrounds. 
Keywords: Globin, Gene Expression, Hematopoiesis, Lineage Specification, Transcription 
Factor 
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Background 
Blood consists of: 
• Red cells 
• White cells 
• Platelets 
• PlasmaI 
Hematopoiesis 
Hematopoiesis is the formation and development of blood cells. Sites of  
hematopoiesis include the bone marrow, liver, spleen, lymph nodes and thymus. The blood 
cells have the particular ability for persistent production which demands tight regulatory 
system. Pathological processes interfering with normal production can lead to an excess 
(hyperplasia; e.g., leukemia) or an inadequate number of cells (hypoplasia; e.g., anemia, 
thrombocytopenia, or leukopenia).1 
Hematopoietic Stem Cell (HSC) 
Hematopoiesis begins at embryonic period when blood islands are formed in the 
yolk sac in the third week of gestation. Blood islands are the source of primitive blood cells 
till these cells migrate to liver and spleen. These organs are the main sites of hematopoiesis 
from six weeks to seven months, when eventually the bone marrow becomes the center of 
hematopoiesis. After birth, the bone marrow is the only source for production of blood cells 
and hematopiesis takes place in the marrow of nearly all bones. Reaching adulthood, 
hematopiesis becomes confined to the bone marrow of central skeleton and the proximal 
                                                 
I
 Plasma is the liquid component of blood where blood cells are suspended. 
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ends of long bones (Figure-1), in which all blood cell types are derived from pluripotent 
stem cells, termed as hematopoietic stem cells (Figure-2).2 
 
Figure 1- Hematopoiesis in humans. Anatomical location of hematopoiesis change during human 
development.3  
Stem cells have been found in practically every tissue. Like other stem cells, HSCs 
are characterized by two clonal properties: self-renewal, the hallmark property of stem 
cells, is the production of more stem cells with the maintenance of an undifferentiated state, 
and the second is the extensive proliferation and differentiation capacity to generate 
differentiated progeny to commit to one specific cell line (lineage-specification). Excess or 
inadequate production of hematopoietic cells will end in various disease states.4   
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Figure 2- Hematopoiesis and stromal cell differentiation.5  
Lineage specification of HSCs. HSCs produce a variety of differentiated cell 
lineages, depending on intrinsic cell programming and the micro-environmental signals.6 
The stem cell plasticity and lineage commitment are shown to be regulated by a sequential 
expression of hematopoietic genes and are the result of transcription control in concert with 
chromatin remodeling and epigenetic modifications. Lineage specification and cellular 
maturation begins by alteration in cellular gene expression profile, which commits the cell 
to a specific lineage, and continues by the establishment of lineage-specific gene 
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expression. All these decisions are entirely made by temporal and spatial activation of 
certain lineage-specific genes and repression of the others. Commitment to a given lineage 
is mediated by many ubiquitous and lineage-specific transcriptional regulatory proteins that 
activate lineage-specific gene expression programs and extinguish expression of lineage-
inappropriate genes.7,8  
Erythropoiesis 
Erythropoiesis is the process of red blood cell (RBC) formation and development. 
Red cell precursors pass through several stages in the bone marrow to produce mature red 
cells (erythrocytes). As development progresses, at each stage, cells contain less RNA and 
more hemoglobin (Hb) in the cytoplasm. The cell becomes smaller, and the nucleus 
becomes more condensed and eventually is lost, when the cells are released into circulation 
as reticulocytes. After 1-2 days, reticulocytes lose their RNA and shape into non-nucleated 
biconcave discs, namely mature red cell (erythrocyte).9 
Hemoglobin Synthesis 
 The characteristic red color of blood is from hemoglobin (Hb). Hemoglobin is the 
main protein in the red blood cells that carries oxygen (O2) from lungs to the rest of the 
body and returns carbon dioxide (CO2) from the tissues to the lungs. This critical 
performance is governed by the biconcave shape of RBCs, providing a large surface area 
for oxygen and carbon dioxide exchange, and by high affinity of Hb for oxygen and carbon 
dioxide in lungs and body tissues, respectively.10 Hemoglobin is also involved in 
transportation of a third gas, Nitric oxide (NO), which is important in  regulation of blood 
pressure by vasodilation and increasing blood flow.11 
Different types of hemoglobin are produced during development from embryonic 
period to adult life. Each hemoglobin molecule consists of two α-like (141 amino acids) 
and two β-like (146 amino acids) chains forming a tetramer. Each globin chain tightly 
enfolds a non-protein heme moiety in a “pocket”, consisting of a single iron atom (Fe2+) at 
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the center held in a heterocyclic protoporphyrin IX ring with an optimal position for 
reversible oxygen binding. Four molecules of oxygen can therefore bind to and be 
transported by one hemoglobin molecule.12  
The “blueprint” for hemoglobin synthesis exists in two tightly linked loci, α-like 
globin genes clustered on chromosome 16II and the β-like globin genes clustered on 
chromosome 11, with four genes encoding each polypeptide chain during development 
(Figure-3).13  
 
Figure 3- Hemoglobin structure. hemoglobin is a hetero-oligomeric protein contains two α and two 
β subunits arranged with a quaternary structure.14  
At least six different types of hemoglobin molecules are formed, in steps, following 
the sequential expression of α- and β-globin gene clusters in process of human development 
(Figure-4). Hb A (α2β2) is the major hemoglobin in adults with about 97% while two other 
types, Hb A2 (α2δ2) and Hb F (α2γ2), are found only in small amounts, 1.5-3.2% and <1%, 
respectively. HbF (α2γ2) predominates during most of gestation period.15 
                                                 
II
 The α-like cluster consists of two α-globin genes and a single copy of the ζ gene. These genes are similarly 
arrayed in the order that they are expressed during ontogeny. 
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Figure 4- Types of normal hemoglobin. Different normal hemoglobin variants involve genes both 
from the alpha and beta gene clusters. Hemoglobin A (α2β2) is the normal hemoglobin that exists after birth. 
Hemoglobin A2 (α2δ2) is a minor component (< 3%) of the hemoglobin found in red cells after birth. 
Hemoglobin F (α2γ2) is the main hemoglobin during fetal development.16  
Hemoglobinopathies  
Hemoglobinopathies, hemoglobin disorders, are genetic defects that results in 
qualitative (sickle cell disease) or quantitative (thalassemias) change in the hemoglobin 
molecule.17 
Thalassemia. Thalassemia is a hereditary underproduction of either the alpha or 
beta globin chains of the hemoglobin molecule resulting in a hypochromic, microcytic 
anemia. Gene deletion results in variable levels of disease. There are four genes coding for 
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the alpha chain of hemoglobin. There can be deletions of one, two, three or all four genes. 
Beta thalassemia can be mutated in either one or two genes.18  
The clinical presentation of these disorders is dependent on the number of abnormal 
genes. In alpha thalassemia one gene deleted yields a normal patient. Individuals with two 
genes deleted have a mild anemia while those with three genes deleted have more profound 
anemia where beta chains form tetrads, namely hemoglobin H. Four-gene-deleted alpha 
thalassemia patients die in utero secondary to gamma chain tetrads called hemoglobin 
Barts. In one-gene-deleted beta thalassemia (thalassemia minor, thalassemia trait), there is a 
mild anemia with marked microcytosis. Patients with thalassemia major are homozygous 
for mutations of both genes coding for the beta hemoglobin gene. These patients with beta 
thalassemia major, also known as Cooley anemia, become severely symptomatic starting at 
six month of age when the body would normally switch from fetal hemoglobin to adult 
hemoglobin. They show severe symptoms of growth failure, hepatosplenomagaly, jaundice, 
and bony deformities secondary to extramedullary hematopoiesis. Later in life, they are 
symptomatic from hemochromatosis, cirrhosis, and congestive heart failure from chronic 
anemia and transfusion dependence. In beta thalassemia, there is an increased level of 
hemoglobin F and A2. Those with alpha thalassemia will have normal amounts of 
hemoglobin F and A2. 
Thalassemia trait of both the alpha and beta types do not require specific treatment. 
Beta thalassemia patients require blood transfusions once or twice a month accompanying 
with iron chelating therapies with Deferasirox as the standard of care.19 A small number of 
patients can be treated with hematopoietic cell transplantation.20 
Sickle Cell Disease. Sickle cell disease is an autosomal recessive hereditary disease. 
Hemoglobin S is due to a substitution of a valine for glutamic acid as the sixth amino acid 
of the beta globin chain. Almost all of those with the trait are asymptomatic. Those with 
sickle cell disease (SS) typically have mild to moderate anemia with irreversibly sickled 
cells and recurrent painful crises. Elaborate therapeutic modalities are beyond the scope of 
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what is neither necessary nor relevant to know for this thesis. Bone marrow transplantation 
can be curative but still be considered experimental at this time.21 
Human β-globin locus 
The human β-globin locus consists of five functional genes; ε, Gγ, Aγ, δ and β, 
organized in the order of their developmentally timed expressionIII (Figure-5). These genes 
reside within ≈ 50 kilobases (kb) of chromosomal DNA in the transcriptional activation 
during ontogeny and are expressed in cells of erythroid cells.22 Important regulatory 
sequences flank each gene: promoter elements at immediate upstream, and enhancers as 
well as silencers located in vicinity or at distance in the locus.23 Transcription of the β-
globin locus undergoes two sequentially programmed switching during development from ε 
to γ at six weeks of gestation and from γ to δ/β shortly after birth.24 
A powerful set of enhancer elements, namely β-locus control region (β-LCR), exists 
at 5' upstream of ε gene. Human β-globin LCR consists of five developmentally stable, 
DNase I hypersensitivity sites (HSs) and is located 6-30 kb upstream of the ε geneIV.25 
Susceptibility to digestion with DNase I indicates that these regions are, in fact, accessible 
to transcription and chromatin remodeling factors at the time of gene expression.26 The 
enhancer activities of 5'HS2, 3 and 4 resides in core elements (200-300 bp) of individual 
HS sites composed of a wide array of binding sites for ubiquitous and lineage-specific 
transcription factors. 5'HS1-4 are erythroid-specific and 5`HS5 is ubiquitous.27 Another HS 
site (3'HS1) is located downstream of the β-gene. Two additional HSs (5'HS6-7) have also 
been discovered at the 5' end of the β-globin domain (Figure-5).28  
                                                 
III
 A non-expressed pseudogene (ψη) is also located on human β-globin locus.  
IV
 The LCR was first identified in the human β-globin locus, being important in the control of eukaryotic gene 
expression in many other mammalian gene systems. 
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Figure 5- Structure of human β-globin locus. 
The spatial arrangement of β-globin genes with respect to LCR is essential for their 
proper regulation throughout development; i.e. the genes expressed early in embryonic 
stage are closest to the LCR and those expressed in adult life are farthest.29 LCR enhances 
the expression of β-like genes to physiological levels in a tissue-specific and copy number-
dependent manner.30  
Globin gene expression. It is well known that globin gene expression is restricted 
to specific tissues. Recently, the thought that globin gene expression is solely confined to 
erythroid cells is questioned by findings of adult hemoglobin protein in activated 
macrophages and alveolar epithelial cells. However, these cells have shown lower amounts 
of globin polypeptides, comparing to erythroid cells, and different gene regulation 
mechanisms.31 Further studies are yet required to elucidate the patterns and mechanisms of 
hemoglobin expression in these cells during cellular differentiation and under various 
environmental conditions. Moreover, mechanisms required to preclude globin gene 
silencing in alternative hematopoietic lineage are poorly described.  
Considering the hematopoiesis tree, the transcription of the β-globin locus is 
exclusively displayed by erythroid cells, and more importantly, results in erythroid-lineage 
specification. Normal red blood cell differentiation requires the coordinated expression of 
erythroid-specific genes, such as the globin genes and the genes responsible for heme and 
iron metabolism. These processes are under the control of and involve the complex 
interplay of a number of specific growth factors and cytokines such as interleukins, 
granulocytemonocyte-stimulating factors (GM-CSF), stem cell factor (SCF) and 
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erythropoietin (EPO).32 For instance, erythropoietin, a glycoprotein hormone produced by 
the kidney, promotes red blood cell survival through protecting these cells from 
apoptosis.33,34 Also, in the hematopoietic system, stem cell generation, cell fate decisions 
and maintenance (lineage-specification and commitment) and differentiation depends on 
the coordinate activity of multiple transcription factors through transcription factor 
networks interacting with crucial regulatory regions of lineage-specific genes.35,36 That is 
the promise of differentiation towards the production of erythroid-lineage versus non-
erythroid cells. 
Globin gene expression and LCR  
Temporal and spatial control of gene expression are mediated by binding of trans-
acting factors to cis-acting DNA sequence(s) such as promoters, enhancers, and silencers as 
well as long-range cis regulatory LCR elements.37 The LCR was first identified in the 
human β-globin locus over 20 years ago.38 While different in composition and location, 
mammalian β-globin loci of different species, including humans, mice, rats, rabbits, and 
goats contain LCR in part of their genome.39,40  
In human β-globin locus, the regulation of gene expression is achieved by the 
dynamic interactions between cis-acting sequences and trans-acting factors. Proximal and 
distal cis-acting sequences, the LCR and downstream globin gene sequences, establish and 
maintain specific chromatin conformations. trans-acting factors, transcription factors, 
coregulators and chromatin remodeling factors, initiate, regulate and determine the final 
level of gene expression control.41 Modulation of chromatin structure can have opposite 
effects on gene regulation as activation versus repression.42 Dynamic chromatin 
configuration as open, resulted from histone modification (histone acetylation), or closed 
chromatin, due to DNA methylation and histone deacetylation, is quite central to tissue-
specific developmental control of β-globin gene expression.43 In general term, the open 
chromatin is defined as DNase I-sensitive and hyperacetylated state of histone composing 
the chromatin, whereas closed chromatin is DNase I-insensitive and underacetylated. Such 
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chromatin structure fluctuation between “open” and “closed” conformations is mediated by 
chromatin-remodeling complexes that are concomitantly associated with both LCR and β-
like globin promoters to facilitate interactions between transacting factors and DNA. 
Chromatin remodeling complexes modulate chromatin structure to promote binding of 
erythroid-specific and ubiquitous transcription factors at both LCR and the gene promoters. 
Such modulations assist the assembly of the transcription apparatus required for full level 
of expression in erythroid cells while accompanies inactive chromatin structure in non-
erythroid cells. These complex interactions determine the transcriptional status as well as 
the final level of β-like globin gene expression. 44,45 
While located at a considerable distance from the site of transcription initiation, 
LCR controls the overall level of expression of β-globin genes as a key regulator of the 
locus chromatin organization. Chromatin is in "open" state at LCR throughout development 
but its state at β-globin genes is determined by the expression order of target genes during 
ontogeny; that is open at ε-/γ-globin domain during embryonic/fetal period but closed 
during adult erythropoiesis. The reverse state exists for adult δ-/β-globin domain.46 LCR 
role in chromatin-opening and in maintaining of an open chromatin state is essential for 
recruitment of additional chromatin remodeling factors, necessary for further opening of 
chromatin, or of other transcription factors, involved in high level of expression.47 
Several models have been proposed to elucidate how the LCR exerts its regulation 
on transcription from such a long distance. From four most prevalent models proposed for 
LCR functionV, looping model is more acceptable to explain the mechanisms underlying 
the LCR interaction with the globin genes. All these models indicate that LCR alters 
chromatin configuration. The looping model implicates that LCR loops back on itself to 
fold into a “holocomplex” without straining the backbone bonds of the DNA double helix. 
More significantly, this allows the locus to form a spatial conformation and take hold of a 
physical close proximity to the desired gene, which facilitates the interaction of 
                                                 
V
 These four models are looping, tracking, facilitated tracking and linking models. 
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transcription factors bind to LCR with those at promoters. This proximity secures the 
interaction of LCR-bound transcription factors and/or coactivators with basal transcription 
factors bound at the promoter. 48,49 
Data from studies on some forms of thalassemiaVI containing deletion in LCR 
region have supported the indispensable role of LCR in expression of β-globin genes. 
While these forms of thalassemia carry intact β-globin locus, globin genes are not 
expressed. These deletions result in closed chromatin configuration of globin locus, 
normally opened by LCR, and thus the suppression of gene expression occurs. These 
natural occurring deletions of the LCR such as in Hispanic thalassemia, provide the 
evidence that the LCR is critical for the chromatin organization of the locus.50 
The presence of LCR for globin gene expression is important since its absence shuts 
down β-globin gene expression to less than 1%. The most prominent property of the LCR is 
strong transcription-enhancing activity. However, not all HS sites have the same 
importance in this respect. The main enhancer activity is conferred by 5'HS2, 5'HS3, and 
5'HS4, and not 5'HS1 or 5'HS5.51 The interaction of regulator transcription factors with 
LCR HS sites and with each other is essential for high-level of globin gene expression at 
different developmental stages.52 Deletion of the HS core element from 5`HS2, 3, or 4 
abolishes normal LCR function due to disruption of the DNase I-hypersensitivity sites 
holocomplex and preclude proper interaction with promoters but when there is no position 
effect, the disruption of one HS does not impair the other HS site formation.53 Even the 
orientation of LCR HS elements is central for proper functioning; that is, a synthetically 
inverted LCR has been associated with low level of globin gene expression throughout 
development. This suggest that The LCR transcription enhancer activity is directional.54 At 
any specific stage of hematopoietic cell differentiation, different transcription machinery 
complex is stabilized on LCR, according to transcription factor milieu, whereby an 
enhancement in globin gene expression is achieved. The LCR, similar to globin genes, has 
                                                 
VI
 Hispanic β-thalassemia 
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tissue-specific enhancing activity which more specifically confines the expression of globin 
genes to erythroid cells. In essence, developmental and lineage-specific regulation of gene 
expression results from the complex interaction of gene-proximal elements with distant cis-
regulatory elements on a bed of  chromatin. 
Globin gene expression and transcription factors. Complex genetic programs 
determine survival, proliferation, differentiation and function of hematopoietic cells during 
different steps of hematopoiesis. Gene expression is controlled at various points between 
the translation of DNA to proteins with transcriptional control be the most important point 
of regulation for many genes. Gene transcription is possible only when DNA-binding 
proteins come together, assemble and interact with the promoters, the operators and the 
enhancers. The existence of multiple regulatory regions and varied DNA-binding proteins 
helps a given gene to precisely control its expression at a basal level and/or up- or down-
regulate the expression in response to cellular stimuli for differentiation and/or 
proliferation. In hematopoiesis, many of these protein complexes are lineage restricted and 
act as cell type-specific transcription factors.55 
Globin gene expression is regulated by the dynamic interplay between transcription 
factors and epigenetic mechanisms. Many transcription factors have been shown to control 
β-globin gene expression through the formation of intricate transcription factor networks 
(TFNs) and by binding several cis-acting elements on locus, followed by recruitment of 
additional regulatory proteins (cofactors) via direct protein-protein interactions.56 General 
transcription factors (GTFs)VII and different lineage-specific transcription factors should 
bind the promoter and LCR of β-genes to mediate the tissue- and stage-specific expression 
of the β-like globin genes. Some of these factors are ubiquitous (e.g., Sp1 and YY1), while 
others are tissue-restricted and more or less limited to erythroid cells (e.g., GATA-1, NF-
                                                 
VII
 GTFs or basal transcription factors are proteins that either bind DNA or take part in the formation of a 
preinitiation complex (PIC), and used by RNA polymerase II to begin and proceed with transcription. The 
most important GTFs are TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH. 
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E2, TAL-1 and EKLF). These transcription factors turn on/off the transcription 
appropriately to fit the gene-expression profile for cell fate determination and cellular 
differentiation. It is becoming increasingly clear that these factors do not operate 
independently but as part of large multi-protein complexes.57  
Given the formation of large multiprotein complexes, certain transcription factors 
can engage in functional interactions, via these complexes, while lacking sequence-specific 
activity. Indeed, a single transcription factor can employ numerous mechanisms to control 
transcription and thus, one cannot to consider the function of a particular hematopoietic 
transcription factor independent of complex partners and apart from important functional 
interplays. Herein, it is unfeasible to comprehensively review all transcription factors 
implicated in erythropoiesis, but short recapitulation of some potential lineage-specific 
transcription factors would be relevant for our study. 
Transcription factors and  Erythropoiesis (Table-1)  
GATA-1 is a master regulator gene critical for erythroid cell formation.58 It interacts 
with several transcription factors; CBP/p300, PU.1, Sp1 and erythroid Kruppel-like factor 
(EKLF), through different multiprotein complexes to activate adult β-like globin genes.59 
The PU.1-GATA-1 interaction60 and the balance between GATA-1 and GATA-2 levels are 
required for precise lineage specification.61 While GATA-1 expression is observed in 
erythroid, mast cell, and megakaryocyte lineages, GATA-2 is expressed in certain 
hematopoietic precursors and is crucial for the survival and proliferation of HSCs.62 During 
erythropoiesis, GATA-1 level increases and displaces GATA-2 on hematopoietic target 
genes so that different genes expressed in accordance with GATA switch.63 Such GATA 
switch is facilitated in virtue of friend of GATA-1 (FOG-1) activity. FOG-1 is a protein 
whose expression mimics that of GATA-1 and is essential to stimulate erythropoiesis.64 
FOG-1 helps GATA-1-mediated looping by which LCR comes close to adult β-globin 
genes.65 In addition, PU.1 antagonizes GATA-1 DNA binding and thus blocks 
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erythropoiesis in favor of granulocyte and monocyte, B and T lymphocyte differentiation. 
The antagonistic interaction of GATA-1 and PU.1 drives hematopoiesis via common 
myeloid progenitor (CMP) cells into granulocyte macrophage progenitor (GMP) cells or 
megakaryocyte erythroid progenitor (MEP). While sufficient levels of PU.1 will produce 
GMP lineage, higher levels of GATA-1 (comparing to PU.1) will moves differentiation to 
MEP. Also, GATA-1 exists in a multiprotein complex called SCL complex with LMO2, 
E47 and Ldb1 in different hematopoietic cells at distinct stages of hematopoiesis.66  
Stem cell leukemia (SCL), also known as T-cell acute lymphocytic leukemia-1 
(TAL-1), belongs to class II HLH proteins and has tissue-restricted and lineage-specific 
patterns of expression.67 TAL-1 is known to be essential for haematopoiesis. The TAL-1 
gene is normally expressed in haematopoietic progenitors, erythroid lineage cells, mast-cell 
lineage cells, megakaryocytic lineage cells and endothelial cells.68 TAL-1 dimerizes with E 
proteins (E47) and functions at multiple stages of hematopoiesis. SCL complex binds a 
composite motif consisting of a GATA motif and an adjacent E-box.69 SCL also stimulates 
the generation of hemangioblasts to differentiate into both blood and endothelial cells.70,71 
Alteration in TFNs or dysregulation of signaling and transcriptional function leads 
to neoplastic transformation of hematopoietic cells and consequently the progression of 
specific leukemias. In the same way, the genes responsible for heme and iron metabolism 
ought to specifically be expressed during erythropoiesis to conform to RBC 
differentiation.72 
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Transcription Factor Gene Function 
GATA-1 GATA-1 Erythroid and Megakaryocytic development 
Erythroid Krüppel-like 
Factor (EKLF) 
EKLF Maturation of erythroid cells, Chromatin 
remodeling, Modulation of the gamma to beta 
globin switch, Transcriptional activation, 
Binding to the CACC motif of the β globin 
gene promoter 
Nuclear factor erythroid-
derived 2 (NFE2) 
NFE2 Interaction with CREB binding protein 
Stem cell leukemia 
(SCL) or T-cell acute 
lymphocytic leukemia-1 
(TAL-1) 
TAL-1 Generation of HSC  
FOG-1 FOG-1 Cofactor of GATA-1 
p300 and CREB binding 
protein (CBP) 
p300 and 
CREB 
Increase gene expression, histone 
acetyltransferase (HAT) activity, Recruiting the 
basal transcriptional to promoter  
  
Table 1- Role of Transcription factors in Erythropoiesis. 
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Helix-Loop-Helix (HLH) proteins 
There are four basic classes of bHLH proteins classified according to their structural 
motifs. The basic helix-loop-helix (bHLH) proteins are dimeric transcription factors present 
in nearly all organisms from yeast to humans.73 Numerous bHLH proteins have been 
identified in animals, plants and fungi. They are first introduced by Murre C, et al about 
twenty years ago.74  
Helix-Loop-Helix (HLH) proteins: Regulators of transcription in eukaryotic 
organisms. The fundamental roles of these transcription factors are established in a broad 
spectrum of cellular and molecular events involved in the regulation of commitment, cell 
growth and differentiation of various cell lineages during embryonic development, 
particularly neurogenesis, myogenesis, retinogenesis and hemetopoiesis.75 The followings 
are a few examples: BETA2 (NeuroD1) is a member of bHLH proteins and studies on 
mouse animal models have shown that it plays an important role in the development of the 
central and peripheral nervous system.76 Muscle Regulatory Factors (MRFs) of the bHLH 
proteins; MyoD, Myf5, Myogenin and MRF4 are sequentially expressed during skeletal 
muscle formation and coordinate the expression of muscle-specific genes required for 
skeletal muscle development in embryo. MyoD and myogenin work as dimmers to drive 
appropriate myogenesis.77 Any of retinal photoreceptor cell lineages carries an exclusive 
bHLH context during retinal neurogenesis, which highly emphasizes the cell-specific 
property of bHLH transcription factors.78 NeuroD acts as important regulator at some point 
in rod and cone photoreceptor genesis.79 
Classification and structure. bHLH transcription factors bear sequence homology, 
with overlapping and analogous expression patterns, and highly conserved DNA binding 
specificity. Members of this family contain two highly conserved domains at either end. N-
terminal (AD1 domain) is a basic DNA binding domain that helps the transcription factor to 
bind to DNA at a consensus hexanucleotide sequence of G(orA)CAXXTGG(orA), namely 
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E-box. At the C-terminal (AD2 domain), there is HLH dimerization domain which is 
involved in formation of hetero- and homo-dimers with other members of bHLH family.80 
Figure-6 shows the structure of MyoD that stands up for the feature structure of many 
bHLH proteins consisting of two amphipathic long α helices connected by a short loop that 
mediates homo- and heterodimerization. 
 
Figure 6- Structure of a MyoD basic-helix-loop-helix (bHLH) transcription factor.81 
The phylogenetic classification of bHLH proteins as four groups of proteins named 
A, B, C and D is illustrated in Table-2.82 The bHLH proteins can show ubiquitous (E47, 
E12, HEB and E2-2) and tissue-restricted (MyoD and neuroD) expression. Class I bHLH 
proteins (E proteins) are comprised of four members encoded by three distinct genes: E2A 
(E12 and E47 known collectively as the E2A proteins)VIII encoded by Tcfe2a gene through 
different splicing, E2-2 and Hela E-box binding protein (HEB). The two former has 
                                                 
VIII
 Synonyms are Immunoglobulin Transcription Factor-1 (ITF1) and Transcription Factor-3 (TCF-3) 
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different DNA binding affinity with higher affinity for E47. HEB and E2-2 show similar 
DNA binding activity.83 The variety in tissue distribution, DNA-binding characteristics and 
the capacity for homo/hetero dimerization provide bHLH with high functional diversity and 
specificity. Moreover, the transcriptional activity of the bHLH proteins are modulated by 
IdIX (inhibitor of differentiation) proteins which in turn confers far more functional 
diversity with respect to the formation of inactive heterodimers that inhibit bHLH proteins 
from binding to the E-box sites and activating gene transcription.84,85 
 
Table 2- Classification of bHLH proteins. 
                                                 
IX
 Id proteins are helix-loop-helix (HLH) proteins consist of four isoforms (Id1, Id2, Id3, and Id4), with 
homologous HLH domain, that lack the DNA binding basic domain. Id proteins regulate cell type-specific 
gene expression during cell proliferation, differentiation and commitment, cell cycle, and apoptosis. Acting as 
negative regulators of bHLH transcription factors, Id proteins are considered as dominant negative regulators 
of differentiation pathways. 
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E proteins and hematopiesis. Multiple basic helix-loop-helix (bHLH) genes play a 
critical role in regulation of hematopietic cell proliferation and differentiation. The function 
of E proteins in lymphocyte development and differentiation, and their role in lymphoma 
development is addressed on a large scale, but very little is known yet about the 
mechanisms through which E proteins may contribute to myeloid lineage specification, and 
particularly erythropoiesis. Functional heterodimers between the E proteins and other 
tissue-specific bHLH regulators have been observed. E proteins bind to E-box motif 
(NNCANNTGNN) on their target genes as either heterodimers with Class II bHLH proteins 
in non lymphoid cells or homo/hetero dimmers in lymphoid cells.86  
E proteins in lymphoid-lineage. Research on E proteins has identified that the E 
proteins contribute to B lineage- and T lineage-specific gene expression programs by which 
they regulate lymphocyte survival and cellular proliferation. The expression of several 
lymphoid lineage-specific genes is regulated through different types of hetero/homodimers, 
of which the presence of E2A is indispensable.87 E2A drives HSCs to the establishment and 
generation of early B cells by activating B cell-specific gene expression programs and 
immunoglobulin heavy chain (Igh) gene rearrangement. The function of E2A proteins as 
transcriptional activators is imperative for the completion of immunoglobulin gene 
rearrangement and normal lymphoid cell development.88 In E2A knockout mice, B-cell 
development between the pre-B and pro-B-cell stages, at the pro-pre-B stage before 
expression of the IL-7Ralpha, and the rearrangement of the immunoglobulin genes are 
severely disrupted.89 Other studies have revealed complete B cell development block in 
E2A-deficient mouse models.90 
In B-cells, E proteins mainly exist as E47 homodimers, or as E47/E12 heterodimers 
associated with HEB. HEB and E2-2 are necessary for formation of pro-B cells while 
interacting with E2A. That is to say E2A is necessary for B lymphoid commitment while 
for further proliferation and differentiation HEB, particularly, and E2-2 are required at later 
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stages.91 Latest data from generation of double-deficient pre-B cell lines for E2A and HEB 
proteins have confirmed these findings.92  
Directly relevant to above enquiries, the role of the E proteins E2A and HEB during 
T lymphocyte development have been well established. Different combinations of bHLH 
proteins; SCL, E2A and HEB, control the regulation of T-lineage, non-T-lineage and cell 
cycle genes at each stage of T-cell development by activating or repressing receptor-
dependent signals.93 E proteins are expressed all over the stages of T cell development and 
their effects are counteracted by Id proteins to adjust the stepwise transcriptional control 
required for lymphopiesis.94,95 E47 and E12 proteins are important for early thymocyte 
development and similar to the role they perform in B-lineage development, the loss of 
E2A gene activity, in E2A gene-null mice, gives rise to a partial block at the earliest stage 
of T-lineage development and consequently to development of T-cell lymphoma.96 
Similarly, any disruption in HEB expression results in partial block in T-cell 
development.97  
E proteins and ETO family. Transcriptional repression plays a critical role in 
development and homeostasis likewise. Besides the formation of heterodimers with 
inhibitory Id proteins, E proteins can show repressive effects on gene expression through 
the recruitment of different co-regulatory factors to the AD domains. For instance, in 
mammalian cells, AD1 can either activate transcription through recruitment of the histone 
acetyltransferases CBP and p300 or repress transcription by direct recruitment of ETO 
family.98,99,100 E2A activity is inhibited by Id2 through its interaction with E47 DNA 
binding domain and also by repression E47 target gene through the interaction of its N-
terminal domain (AD1 domain) with ETO-2.101,102 Id proteins show inhibitory effects on 
both positive and negative regulatory properties of E proteins and consequently end in 
repression or activation respectively, whereas ETO members might only drive 
transcriptional repression. 
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The ETO family is comprised of three highly conserved and ubiquitously expressed 
transcriptional regulatory proteins encoded by three genes in the mammalian genome: eight 
twenty-one (ETO; MTG8), myeloid transforming gene related protein-1 (MTGR1) and 
myeloid transforming gene chromosome 16 (MTG16; ETO-2). Three closely-related 
murine homologues include mETO, cbfa2t3 (murine homologue of MTGR1) and ETO-2. 
ETO-2 is highly identical to MTG16 suggesting ETO-2 as a murine homologue of MTG16. 
Mouse ETO is 75% identical to ETO-2 and 99% identical to human ETO. These proteins 
interact with a number of transcription factors inside the different multiprotein repressor 
complexes and on the promoters of different target genes.103 
ETO gene products can interact with both nuclear corepressors N-CoR and Sin3A, 
and histone-modifying (chromatin remodeling) proteins histone deacetylase 1 (HDAC-1) 
and histone deacetylase 3 (HDAC-3).104 N-CoR, mammalian Sin3 (mSin3A and B) work in 
concert with HDAC-1 to modify the chromatin structure in favor of transcriptional 
repression.105 ETO has received a large attention because the hybrid gene product 
(AML/ETO), resulting from the translocation of AML (CBF2) gene on chromosome 21 and 
the ETO (MTG8/CDR) gene on chromosome 8, forms a fusion oncoprotein which is 
associated with leukomogenesis and is found in French-American-British (FAB) type M2 
acute myeloid leukemia (AML).106 The proposed explanation for underlying mechanism is 
directly relevant to ETO function as a compelling transcriptional repressor within and in 
interaction with the N-CoR/mSin3/HDAC-1 complex. AML1/ETO fusion may inhibit 
expression of AML1 target genes by redirecting aforementioned repressors, hence could 
inhibit cellular differentiation and disrupt normal hematopoiesis. This HDAC-dependent 
transcriptional repression ensues in a variety of hematologic lineage-specific gene 
promoters and turns out to be a common pathway in the development of leukemia.107 
Data regarding the role of E proteins in erythroid lineage is still limited. Recently, 
Goardon N, et al. has shown that, in erythroid cells, E2A, HEB and E2-2 are within the 
SCL (TAL-1) complex containing ETO-2, HDAC-1 and HDAC-2.108 The function of TAL-
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1 complex is seminal to the regulation of hematopoietic specific genes from HSCs to 
differentiated hematopoietic progenitors in both mouse and human and also for 
differentiation to lymphoid or myeloid progenitors.109 TAL-1/E2A as well as TAL-1/HEB 
heterodimers play important roles in transformation of T-cell precursors.110  
TAL-1 may act as a bifunctional transcriptional regulator (activator and repressor) 
depending on transcriptional coregulators (coactivators or corepressors). TAL-1 is involved 
in a complex transcription network bearing either repression or activation capacity for 
genes whose promoters occupied by TAL-1, E2A, and HEB. E2A, HEB and TAL-1 protein 
levels and their relative ratio as well as their stage-specific transcriptional partners alter 
during hematopoiesis and consequently the expression of their target genes are adjusted and 
lineage-specific gene expression programs are controlled. TAL-1 can either form a 
heterodimers with E2A and HEB proteins, which prevents E2A to form homodimers 
necessary for transcription activation, or recruit other transcriptional repressors. This 
repression effect is proposed as one of the several mechanisms involved in leukomogensis 
(T-ALLX).111 In hematopoietic progenitor cell lines, TAL-1 interacts with ETO-2 through 
E2A/HEB where ETO-2 is recruited on its target promoters via this complex. SCL complex 
gene expression profile is repressed by ETO-2 at the early stage of erythroid differentiation 
and restores, later in process of cellular maturation, by changing in the ratio of TAL-1. 
During erythroid differentiation, the relative ratio of TAL-1/ETO-2 rises in favor of TAL-1 
that reduces the inhibitory effect of ETO-2 over the expression of TAL-1-dependent 
erythroid-specific genes.112 A recent study showed that, upon the induction of murine 
erythroleukemic (MEL) cells and subsequent to detachment of ETO-2 complex from Ldb1 
complexXI the level of ETO-2 decrease which leads to induction of differentiation and 
termination of proliferation (Figure-7).113  
                                                 
X
 T cell Acute Lymphoblastic Leukemia 
XI
 Ldb1 forms a protein complex with TAL-1, E2A, HEB and Lmo2. 
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Figure 7- Model of Ldb1 complexes in uninduced MEL cells. The horizontal arrows indicate that 
the balance of interaction is towards the large complex in proliferating noninduced cells. Upon the induction 
of differentiation and termination of proliferation the level of Eto-2 drops whereas the level of Lmo4 rises, 
hence the equilibrium would shift towards the smaller complexes. The presence of several DNA binding 
proteins in a single complex may explain the role of Ldb1 as a facilitator of long-range interactions. 
Taking together, the fluctuation in concentration of transcription factors and/or their 
cofactors as well as their relative ratio can influence the final composition of protein 
complexes recruited to gene regulatory regions and therefore play a cause-and-effect 
relationship in expression of erythroid genes and in making decisions on differentiation 
versus proliferation. 
Further to clear information from prior studies on animal models and considering 
the insurmountable limitations to the direct experimentation one can perform in human 
populations, the mouse modeling is most effectual to understand the mechanisms involved 
in β-globin gene expression. This study is expected to provide insight into epigenetic 
regulation of β-globin locus during erythropoiesis and help to understand how gene 
expression is regulated in the context of chromatin. Once DNA regions subject to 
transcription factor recruitment are identified, changes in transcription factor networks 
within these sites will be examined in reference to globin gene expression. Herein, we 
attempt to define the affect of bHLH transcription factors on potentiation and basal level 
expression of globin gene in hematopoietic progenitor cells and on high level expression in 
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erythroid cells. In an attempt to investigate the whole β-globin locus, the strategy of present 
project is to focus primarily on HS2, HS3 and promoters of γ-and β-globin genes as these 
regulatory regions are highly essential for expression of globin genes. By this, we would 
reemphasize the harmonizing role of LCR and promoter regions in gene expression. Once 
the components of transcription machinery are identified, we visit knock-out studies, using 
HEB-/- and E2A-/- mouse models transgenic for β-globin locus, to validate our findings. 
This study is designed to deliver an answer to address the molecular mechanisms associated 
with epigenetic modification and transcriptional activation of the β-globin locus and is a 
continuation of what we have been doing orientated in alternative lineage. 
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Applications of study 
Molecular application. Understanding the molecular mechanisms that control 
globin gene expression during development provides us with great insights into basis of 
epigenetic states acquired at multiple levels and shows how they impact globally on gene 
expression. This project will enhance our knowledge about the mechanism of globin gene 
expression. Research in this field has an impact on understanding the basic concepts and 
principles of regulatory mechanisms that coordinately ensure a highly specialized, tissue- 
and stage-specific gene transcription pattern in other loci. This study could broaden the 
horizons of eukaryotic gene regulation as new molecular mechanisms will be discovered 
and existing ones better characterized. 
Clinical application. Molecular investigations of spatial and temporal events that 
control β-like globin gene expression during erythropoiesis would define many basic 
mechanisms underlying or relevant to the pathophysiology of hemoglobinopathies, such as 
sickle cell disease and thalassemia, where the expression of globin genes is disrupted, and 
would eventually lead to development of molecular therapies and/or cures. For instance, 
mutations in strategic regions of genes encoding such transcription factors could serve as 
insults responsible for development and clinical outcome of hemoglobinopathies and 
become in a position of novel targets for gene therapy in future. 
Research Proposal 
Rational 
The stepwise establishment of lineage-specific gene expression profiles, during the 
development of mature blood cells of distinct lineages from HSCs, which progressively 
restrict the differentiation potential and escalate the proliferation potential, makes 
hematopiesis an exceptional model system to study TFNs modulating the expression of 
lineage-specific target genes (Figure-8).114 The human β-globin locus is a highly 
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characterized locus to study the molecular mechanisms of enhancer-promoter interactions 
and to elucidate cell type-specific and developmental-stage specific regulation of gene 
expression. E-box sequences, which are potential binding sites for the bHLH proteins, are 
scattered throughout the β-globin locus within transcriptional regulatory regions at HS core 
elements of 5’HS2 and 5’HS3 as well as promoters of γ- and β-globin genes.115 For this 
reason, these elements are theoretically able to recruit various bHLH proteins and their 
cofactors in the erythroid environment. The animal modeling provides a powerful tool to 
directly test the effects of bHLH proteins recruitment to LCR and promoters of γ- and β-
globin genes on globin gene expression and to determine the mechanisms of these effects. 
Once such mechanisms have been delineated, one can return to human studies to confirm 
key components.  
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Figure 8- Genetic regulatory networks (GRNs) programming hematopoietic stem cells and 
erythroid lineage specification. A control logic model of erythroid development describing known 
interactions important in the development of the erythroid lineage. The genes have been positioned in the 
network so that genes expressed at early developmental stages are positioned towards the top of the figure and 
vice versa. Genes repeated in the network in different positions highlight the different behavior important at 
different stages. 
 45 
 
Hypothesis 
The prevailing hypothesis is that human β-globin locus potentiation and basal-level 
of globin gene expression in multipotent hematopoietic progenitor cells (HPCs) and high-
level of globin gene expression in erythroid cells are the results of both chromatin 
modifying activities and the recruitment of general and lineage-specific transcription 
factors. Informed by key roles of the bHLH  transcription factors in lymphoid lineage-
specific gene expression, we hypothesized that they could regulate the expression of globin 
genes in HPC and erythroid cells as well. We hypothesized that E proteins are recruited to 
both LCR and promoters of γ- and β-genes during the development from HPC to erythroid 
cells alternating with recruitment of ETO-2 and HDAC-1. We also hypothesize that the 
absence of E2A and HEB can affect the transcription (a) through the changes in involved 
transcription factors and/or (b) through the disruption of gene expression. These hypotheses 
will be tested mainly by performing Chromatin Immunoprecipitation (ChIP) assay on 
different sorted populations of hematopoietic cells harvested from wild-type, transgenic and 
knockout mouse models that carry the entire human β-globin locus in their genome. 
Objectives 
The prime objective is to answer the questions, “Are E2A and HEB are components 
of lineage-specific transcription factors recruited to LCR and promoter of globin genes?" 
and "How these transcription factors  are important in terms of globin gene silencing in 
HPCs, high level of globin gene expression in erythroid cells and in alternative lineages and 
how their recruitment change during erythropoiesis?”, using animal models. The project 
aims to investigate the major regulatory sites within the β-globin locus that are occupied by 
E proteins during erythropoiesis in mouse models of human β-globin. With this study we 
aimed to demonstrate the complex system underlying β-globin gene expression with respect 
to E2A, HEB, ETO-2 and HDAC-1. Our results would stand as an important step towards 
gaining a full understanding of processes involved in gene expression. 
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1. To investigate whether E2A, HEB, ETO-2 and HDAC-1 are recruited to 
LCR and promoters of γ- and β-genes in murine erythroid cells and 
hematopoietic progenitor cells (HPCs) as well as human erythroid cells. 
2. To explore how the arrangement of these factors changes during 
erythropoiesis.  
3. Following the experiments on normal genetic background, we extend our 
range of inquiry in knockout mice for E2A and HEB and transgenic for the 
entire human β-globin locus (E2A-/- β+/+ and HEB-/- β+/+), respectively. A 
key question is whether removal of E proteins (E2A and HEB) activity 
might lead to change in the transcription factor complexes at LCR and 
globin gene promoters, particularly in reference to ETO-2 and HDAC-1, 
and/or be disruptive to expression of globin genes. This will enable us to 
take advantage of mouse genetics to further assess the transcriptional 
changes at the levels of progenitors and mature red cells.  
4. Questions persist as to whether the absence of globin gene expression in 
lymphoid lineage could to some extent be due to different factors engaged at 
LCR and globin gene promoters, in which all or none of E2A, HEB, ETO-2 
and HDAC-1 factors may be present. We extend our findings by similar 
exploration of LCR and promoters of γ- and β- genes in lymphoid progenitor 
cells (LPs) in transgenic mice with wild-type genetic background. 
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Mouse models 
Line 2 mouse. The mouse model we used is called line 2 (ln2) which is a transgenic 
mouse for the entire human β-globin locus. This line maintains strong and consistent 
expression of human globin genes and the mice thereof express β-globin genes normally: 
the human transgene is expressed in all murine erythroid cells and each cell that contains 
mouse β-major globin mRNA also contains human β-globin mRNA. This model was 
previously described by Milot E, et al and Strouboulis J, et al.116,117 ln2 mice were 
maintained from homozygous breeder line, available in Dr. Eric Milot’s laboratory, born to 
homozygous mothers crossed with homozygous fathers. 
(E2A +/- ln2 +/+) and (HEB +/- ln2 +/+) mice. Most of both E2A knockout and 
HEB knockout mice die within the first two weeks after birth.XII 118 Homozygous mutant 
mice for E2A and HEB (E2A +/- and HEB +/-) were kindly provided by Dr. Trang Hoang. 
These mice were crossed with male or female of ln2 +/+ background to produce the ln2 
strains heterozygous for the E2A and HEB allele, respectively. After a long process of 
crossing and breeding, E2A +/- ln2 +/+ and HEB +/- ln2 +/+ mice were obtained by mating 
males or females with females or males of same genotype. As discussed above, E2A 
knockout (E2A-/-) and HEB knockout (HEB -/-) genotypes are almost always lethal;119 
therefore, E2A-and HEB-null backgrounds would be best investigated as embryos. For this, 
E2A +/- ln2 +/+ and HEB +/- ln2 +/+ mice were mated with mice of opposite sex and same 
genotype, then the embryos were extracted out from the mothers after cervical dislocation 
on gestational day 13.5 (GD13.5, also called 13.5 dpcXIII). After that, fetal livers were 
extracted and 13.5 dpc fetal liver-derived hematopoietic cells were harvested by flushing 
the fetal livers. DNA was prepared from a fraction of these cells and used in polymerase 
chain reaction (PCR) for genotyping to identify those having E2A -/- ln2 + or HEB -/- ln2 + 
genotype (see Figure 9). With such a cross, the predicted genotype representation for the 
                                                 
XII
 E2A knockout mice are also born at a lower frequency than wild-type mice. 
XIII
 days post coital 
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embryos is equivalent for wild-type, homozygous mutant and knockout. The fetal liver 
erythroid cells (EryC) with E2A -/- ln2 +/+ or HEB -/- ln2 +/+ genotype were utilized in 
the experiments.  
Cell Sorting  
Staining with antibodies (Abs) was performed on ice for 30 minutes followed by 
one wash in phosphate-buffered saline (PBS) 5% fetal bovine serum (FBS). High-speed 
fluorescence-activated cell sorter (FACS) Vantage Flow Cytometer/Cell Sorter machine 
with DIgitalized VAntage (DIVA) option (Becton Dickinson, San Jose, CA) was used to 
analyze and sort the following desired cell populations. For detection of desired 
hematopoietic surface markers, the commercial antibodies were purchased accordingly. 
Nonspecific staining was controlled by isotype-matched control antibodies. Sorted 
populations were always ≥ 90% pure to perform Chromatin Immunoprecipitation assays.  
Murine erythroid cells (Ter-119+) and Murine HPCs (Ly-6C-CD31highc-Kit+) 
Bone marrow cells were harvested from the long bones (tibiae, femora) of adult ln2 
mice. Murine erythroid cells (EryC) were stained with rat anti-mouse Ter119 Abs (TER-
119: sc-19592) followed by goat anti-rat phycoerythrin (PE)-conjugated Abs (Santa Cruz 
Biotechnology, Inc.).  For murine HPCs, cells were stained with rat anti-Ly-6C fluorescein 
isothiocyanate (FITC)-conjugated Abs (ER-MP20: sc-52650) followed by biotinylated rat 
anti-CD31 (BD Pharmingen: 553371), and then goat anti-rat phycoerythrin (PE)-conjugated 
Abs (BD Pharmingen), followed by rat anti-mouse c-Kit (CD117) allophycocyanin (APC)-
conjugated Abs (BioLegend, Catalog # 105812). The populations of ≥ 90% pure HPCs 
were separated by FACS.  
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Murine Lymphoid Progenitors (LPs) (Lin-c-Kit+Sca1+IL-7Rα+) 
We sorted lymphoid committed progenitor population (Lin-c-Kit+Sca1+IL-7Rα+). 
This population is an highly enriched population of common lymphoid progenitors (CLPs) 
that also contains other lymphoid progenitors and hereafter referred to as Lymphoid 
Progenitor (LP) cells.120 LPs were isolated via magnetic Lin+ cell depletion using 
EasySep® negative selection mouse hematopoietic progenitor enrichment cocktail 
(StemCell Technologies, Vancouver, BC: EasySep® Catalog # 19756, EasySep® Magnet 
Catalog # 18000), corresponding to primitive Lin-c-Kit+Sca1+ hematopoietic precursors, 
followed by IL-7Rα+ selection through staining with CD127 (IL-7Rα) antibody 
(BioLegend, Catalog # 121106) and FACS sorting. 108 fresh mononuclear cells were 
suspended in 1ml PBS containing 2% FBS and 2mM ethylenediaminetetraacetic acid 
(EDTA). Medium was Ca2+ and Mg2+ free. Lin+ cells were isolated inside a standard 12 × 
75 mm polystyrene tube placed directly into the magnet, at three steps, firstly by cocktail of 
biotinylated antibodies, secondly by biotin selection cocktail and then by magnetic 
microparticles. The desired Lin- cells were isolated from magnetically labeled unwanted 
Lin+ cells remain bound inside the original tube by pouring off the desired fraction into a 
new polystyrene tube. The purity of these subsets was at least 95%. The lineage restriction 
and the hematopoietic potential of these cells were ascertained by in vitro clonal assays in 
methylcellulose culture for at least one representative sorted population. The appearance 
and distribution of expected colonies and the cellular morphology of this population are 
described earlier.121  
Human primitive progenitor cells (CD34+) 
Human leukapheresis samples were taken from healthy donors after obtaining an 
informed consent.122 Apheresis procedure is designed to mobilize the hematopoietic 
progenitor cells in the patient's blood vessels by treatment with G-CSF (granulocyte 
colony-stimulating factor) cytokine.123 Human CD34+ cells were isolated using human 
CD34 positive selection cocktail (StemCell Technologies, Vancouver, BC: EasySep® 
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Catalog # 18056, EasySep® Magnet Catalog # 18000). 108 fresh mononuclear cells were 
suspended in 1ml PBS containing 2% FBS and 1mM EDTA. Medium was Ca2+ and Mg2+ 
free. CD34+ cells were isolated inside a standard 12 × 75 mm polystyrene tube placed 
directly into the magnet, at two steps, firstly by monoclonal antibodies against CD34 
surface antigen and then by magnetic nanoparticles. A total of five rounds of separation in 
magnet were performed to isolate magnetically labeled (CD34+) cells from unlabeled cells, 
by throwing the unwanted population (magnetic nanoparticle-unbound cells) away. To 
verify the purity of enriched population, the magnetically selected CD34+ cells were stained 
with mouse anti-CD34 fluorescein isothiocyanate (FITC)-conjugated Abs (ICO115: sc-
7324) (Santa Cruz Biotechnology, Inc.) and analyzed by flow cytometry in FACScan 
(Becton Dickinson, San Jose, CA). The results were analyzed using the software CellQuest 
(BD Biosciences). The isolated population was ≥ 98% pure for CD34+ cells. This 
population is described previously.  
 
Genotyping 
Mice were genotyped by polymerase chain reaction (PCR) using DNA extracted 
from tail samples. Mouse tails were cut on postnatal day 21 and digested at 56 °C overnight 
in a solution of 50 mM Tris pH 8.0, 100 mM EDTA, 100 mM NaCl and 1% SDS with 100 
µg/ml proteinase K. Tail genomic DNA was prepared through phenol/chloroform 
extraction. Genotyping was performed using the primers designed to amplify the amplicons 
from β-globin, E2A and HEB genes. For E2A, the common primer 5′- 
TTGTGGACATTTTCTAGGCAG -3′ was used with either 5′- 
CCGAGCTCCTTAAAGGCCTCA -3′ or 5′- CCGAGCTCCTTAAAGGCCTCA -3′ in a 
separate reaction to detect the mutant allele. For HEB, the common primer 5′- 
TCCTGCCTAGTAGGGATTTT -3′ was used with either 5′- 
TCTCACTTGCTGTTCTAGAC -3′ or 5′- TCGCAGCGCATCGCCTTCTA -3′ in a 
separate reaction to detect the mutant allele. For each genotyping run, known genomic 
DNA from E2A-null or HEB-null, E2A heterozygote or HEB heterozygote and wild-type 
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were simultaneously assayed as positive and negative controls. Figure 9 shows one 
representative example of E2A and HEB genotyping that amplified products were loaded 
onto 2% agarose gel, stained with ethidium bromide, and directly visualized under UV 
illumination. 
 
Figure 9- One representative experiment of genotyping (A) E2A and (B) HEB. Ethidium bromide-
stained PCR products were separated on a 2% agarose gel.  
Chromatin Immunoprecipitation (ChIP) assay 
The sorted cell types described above were subjected to Chromatin 
Immunoprecipitation assay in order to investigate the recruitment of transcription factors of 
interest to human β-globin locus. ChIP kits (Catalog # 17-295) were purchased from 
Upstate Cell Signaling Solutions, Lake Placid, NY. Approximately 1.5 - 3 × 105 (Murine 
HPCs and LPs) and 106 (Murine EryC and Human CD34+) cells were used for this 
procedure. To crosslink the factors with the target genomic DNA, cells were incubated at 
37°C for 10 min with 200 µl of PBS containing 1% formaldehyde. Cross-linked chromatin 
was sonicated in order to obtain consistent chromatin fragmentations of ~ 500-bp average 
for 10 seconds on ice and repeated four times. Sonication was optimized prior to real 
experiments. A portion of the sonicated lysate without antibody was separated before 
immunoprecipitation and used as Input chromatin. Following antibodies were raised to 
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isolate the complex by precipitation: anti-E2A (Yae: sc-416)XIV, anti-HEB (A-20: sc-357), 
anti-ETO-2 (G-20: sc-9741), anti-HDAC-1 (Catalog # 06-720, Upstate Biotechnology 
(Lake Placid, NY)), and anti-Histone H3 (di methyl K9: ab7312) (Abcam, Inc., Cambridge, 
MA). ChIP assays were carried out according to manufacturer's protocol with minor 
modifications as described previously.124 The protein/DNA cross-linked nucleosomal 
chromatin complex was reverse cross-linked with NaCl at 65°C for 4 hours. Samples were 
then treated with proteinase-K. DNA was extracted in phenol/chloroform and precipitated 
and washed in ethanol. On average, 1/30 of each ChIP sample was used in quantitative real 
time polymerase chain reaction (QRT-PCR). At least three independent ChIP experiments 
were performed for each transcription factor and the significance of the data was tested 
according to a student t-test.  
Real-time Polymerase Chain Reaction (Q-PCR/qPCR) 
Real-time quantitative PCR analysis of the immunoprecipitated chromatin was done 
by the MyiQ thermal cycler (Bio-Rad) based on SYBER®Green quantification (Qiagen) 
according to the manufacturer's instructions. The primer sequences were designed to 
specifically amplify HS3, HS2, γ- and β-globin promoters using sequence analysis software 
(DNAMAN). Primer sets were tested to assure an amplification efficiency of 90-105% 
using appropriate serial 10-fold dilutions of genomic DNA. Threshold cycles (Ct) were 
determined according to manufacturer software for unbound (input) and for 
immunoprecipitated chromatin. The occupancy of each region by transcription factor of 
interest was calculated relative to input chromatin as described by Geisberg JV, et al.125 
Data were presented as fold enrichments over the values obtained for internal control using 
primer sets specific for the regulatory region(s) (promoter) of mouse THP (kidney-specific 
Tamm-Horsfall gene) or human pax6 (pax6, paired box protein 6). Each PCR was done in 
triplicate for each sample, data was calculated using 2-∆∆Ct formula and results were 
presented as mean ± SD considering a value of 1 as no enrichment. The amplicons were 
                                                 
XIV
 Anti-E2A (Yae): sc-416 detects both E47 and E12. 
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confirmed by a specific melting curve and by the presence of expected band size on the 
electrophoresis gel and ethidium bromide staining.  
Real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)  
RNA was extracted from aforementioned number of sorted cells using Trizol 
Reagent (Invitrogen Life Technologies). RNA was resuspended in 50µl of H20DEPC and 
quantified by spectrophotometry. The total cDNA was synthesized from 1µg RNA using 
with oligo(dT)15 primers and SuperScriptTM Reverse Transcriptase enzyme (Invitrogen Life 
Technologies, Catalog # 18053-017) by incubating for one hour at 37°C, followed by 
incubation of 15 min 70°C to inactivate the enzyme. The RNA has previously been treated 
with 1U DNaseI-RNase free, grade amplification (Invitrogen Life Technologies) for each 
microgram of RNA. cDNA was used in real-time PCR (iCycler iQTM, Bio-Rad) with 
Qiagen QuantiTect probes specific for human β-globin cDNA (5'- 
TCGGTGCCTTTAGTGATG- 3' and 3'-TTGCCCAGGAGCCTGAA -5'; TET-labeled 
QuantiProbe: ACCTTTGCCACACTGA; human βRT) or mouse gapdh cDNA (FAM-
labeled QuantiTect gene expression assay, Qiagen, GapdRT). To avoid genomic DNA 
contamination, human βRT and GapdRT primers were designed to span intron-exon 
junctions. human βRT and GapdRT PCR reactions were independently run at least in 
triplicate. Quantitative real-time RT-PCR analysis was carried out as described in Bottardi 
S, et al.126  
Western blot 
Prior to ChIP experiments, the specificity of antibodies mentioned above and used 
against factors of interest were analyzed by Western blotting considering their specific 
Molecular Weight (MW). The total protein extracts were obtained in sample buffer 
(100mM Tris pH 6.8, 200mm DTT, 4% SDS, 0.2% Bromophenol blue and 20% glycerol), 
and then extracts were sonicated twice for 5 sec and boiled for 5 min. The protein extracts 
were then separated by SDS/PAGE (SDS-polyacrylamide gel 15%), followed by a blotting 
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onto Hybond ECL nitrocellulose membranes (Amersham Biosciences). The membrane was 
blocked with skim milk (5% in PBS). The membrane was then incubated for 16 hours at 
4°C with the primary antibodies diluted with skim milk (1% in GER) at a concentration of 
1: 100. The secondary antibody goat anti-mouse IgG conjugated to peroxidase (Sigma) was 
diluted with skim milk (1% in GER) at a concentration of 1: 1000 and incubated for 2 hours 
at room temperature. After each antibody, the membrane was washed three times for 10 
min in 0.05% Tween 20 in the TBS. The secondary antibody was revealed with a kit 
chemiluminescence ECL Plus (Amersham Biosciences), and then hybridized membrane 
was processed with the phosphoimaging system LAS-3000 (Fuji Life Science) using 
ImageQuant software. Mouse β-actin housekeeping gene was used on the same blot as a 
loading control and for comparative estimation of the protein amount applied to the gels. β-
actin-specific monoclonal antibody (I-19: sc-1616) was used.  
in vitro clonogenic assays   
To determine differentiation potential of Murine HPCs, FACS-sorted cells were 
cultured in Methocult® GF M3434 (Stem Cell Technologies, Vancouver, BC, and Catalog # 
03434). Single cultures contained 50, 100, or 200 Ly-6C-CD31highc-Kit+. The cells were 
cultured in a humidified atmosphere containing 5% CO2. Hematopoietic colonies were 
determined and scored by inverted microscope at three days, for CFU-E (colony-forming 
units-erythroid) and at 14 days, for BFU-E (burst forming units-erythroid), CFU-G 
(granulocyte colony-forming units), CFU-GEMM (colony forming units-granulocyte-
erythroid-macrophage-megakaryocyte), after the cultures were initiated. To examine 
lymphocyte colony formation, LPs (Lin-c-Kit+Sca1+IL-7Rα+) were cultured on Methocult® 
GF M3630 (Stem Cell Technologies, Vancouver, BC, and Catalog # 03630) containing 
rmIL-7 to support growth of pre-B colonies. The colonies were enumerated using an 
inverted microscope after seven days in culture. 
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Erythroid Krüppel-like Factor (EKLF) is an erythroid transcription factor belonging 
to the zinc-finger family of DNA binding proteins.127 EKLF is essential for the proper 
maturation of erythroid cells. EKLF knockout mouse are lethal because of anemia resulting 
from cessation of adult β-globin transcription. EKLF role in β-globin gene expression is 
mediated by its role in chromatin remodeling, modulation of the gamma to beta globin 
switch and transcriptional activation of β-globin gene.128,129 
This manuscript is the first demonstration that EKLF directly binds the globin locus 
in progenitor cells. Previously, our group proposed this idea according to the genetic 
analysis and in this paper, using ChIP assays, our results directly showed the binding of 
EKLF to crucial regulatory regions on β-globin locus and thus emphasizes its role in β-
globin gene expression.  
Alireza Fotouhi Ghiam provided and analyzed the data of EKLF and participated in 
interpretation of results and drafting the manuscript. Some results that were not included in 
the paper is now provided in supplementary section of this chapter to complete the 
information on this subject. The importance of these findings is also discussed. 
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HEMATOPOIESIS AND LINEAGE SPECIFICATION 
Hematopoiesis consists in a progressive restriction of cell fate capacities from 
hematopoietic stem cells (HSCs) to mature blood cells. Lineage specification and cell 
commitment can be achieved by precise activation and/or repression of specific genes. It is 
now accepted by most that lineage specification does not depend solely on single master 
regulators. Rather, it appears to result from precise combinations of specific transcription 
factors, which cooperate to form the so-called transcription factor network (TFN).130 131 
TFs that compose the network will act in a concerted way to regulate gene expression, 
thereby providing cellular identity. A good example of TFN complexity and its impact on 
lineage specification and cell commitment is the role of Pax5, E2A, EBF, and Ikaros during 
B lymphopoiesis. 132 133Although the underlying mechanisms are not yet fully decorticated, 
these TFs are known to influence B lymphopoiesis in a highly coordinated manner. Pax5 is 
expressed at low level in multipotent HPCs134 and can activate B lineage specific genes 
while repressing myeloid genes.135 136 For example, Pax5 induces c-fms gene repression by 
direct interaction and inhibition of PU.1 transcriptional activation.137 Another example of 
alternative lineage suppression138 due to direct TF interactions is provided by the 
interaction of GATA-1 or -2 with PU.1. GATA factors inhibit PU.1 expression and 
transactivation,139 140 and PU.1 acts similarly on GATA proteins (transrepression). PU.1 is 
essential for myeloid and lymphoid specification, whereas GATA-1 is required for 
erythroid differentiation. Likewise, PU.1 and C/EBPα antagonize each other during HPCs 
commitment towards neutrophils or monocytes.141 142 
The variable influence that TFs exert on gene expression can be explained by the 
interplay between TFs and cofactors such as chromatin modifying and/or remodeling 
proteins. For example, in lymphoid cells, Ikaros can associate with Mi2b, HDAC1 (histone 
deacetylase 1) and HDAC2, which are components of the nucleosome remodeling and 
deacetylation (NuRD) complex.143 However, in adult erythroid cells Ikaros is part of the 
PYR complex, which targets to the β-globin locus two types of chromatin remodeling 
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activities that activate (SWI/SNF, as BAF57, BAF155, BRG1) or repress (NuRD, as 
HDAC2, Mi-2) gene transcription.144 
Interestingly, also in the same cell type a given TF can function both as an activator 
and a repressor of gene transcription. This duality is explained by the fact that interactions 
between lineage-specific TFs and cofactors vary according to the gene regulatory region 
targeted. For instance, GATA-1 and its cofactor FOG-1, can function as activators at 
certain gene promoters (α- and β-globin, EKLF, glycophorin A) and as repressors at others 
(GATA-2, myc, myb) by forming distinct protein complexes. In fact, it is reported that in 
erythroid cells, the GATA-1/FOG-1/MeCP1 complex represses hematopoietic genes, 
whereas the interaction between GATA-1 and TAL-1 activates erythroid-specific genes.145 
In addition to the above mentioned, TF protein levels contribute to lineage-specific 
gene expression. Among others, TAL-1, HEB and E2A protein levels have been shown to 
fluctuate during hematopoiesis. In hematopoietic progenitors, TAL-1 interacts with ETO2, 
and via E2A/HEB recruitment, they are both targeted to gfi-1b, p21cip, and GPA 
promoters.146 ETO2 recruits several members of the HDAC family and therefore 
participates in the repression of specific genes including the ones listed above.147 In 
hematopoietic progenitor cell lines, GPA is poorly transcribed and the TAL-1 complex 
recruited at GPA promoter consists of HEB, E2A and ETO2. During erythroid 
differentiation, TAL-1, E2A and HEB expression levels increase, thereby is changing the 
relative ratio TAL-1/ETO2 in favor of TAL-1. This reduces the inhibitory activity of ETO2 
and relieves TAL-1-dependent erythroid genes repression.148 Similarly, in erythroid cells 
the Ldb1-Lmo2-TAL-1-E2A-GATA-1 complex binds to globin LCR and β-gene 
promoter.149 Recently Meier and collaborators150 have demonstrated that this complex also 
includes ETO-2 and that upon erythroid differentiation of mouse erythroleukemic (MEL) 
cells the level of ETO2 and ETO-2/Ldb1 complex decreases, while the level of Lmo-4 
increases. They propose that the level of the large Ldb1-ETO2 complex drops to be 
replaced by one with Lmo-4 to allow late erythroid genes to become activated. Therefore, 
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relative variations of TFs or cofactors concentration can, by itself, influence the 
composition of protein complexes recruited at gene regulatory regions and consequently 
their activating or repressing activities. 
POTENTIATION AND GENE PRIMING IN HPCs 
In embryonic stem (ES) cells as well as HPCs several lineage-specific genes are 
located in transcriptionally potent chromatin i.e., chromatin in an open conformation which 
allows access of TFs and transcriptional machinery to gene regulatory regions. It is in fact 
proposed that most of the hematopoietic-specific genes are potentiated before their 
transcriptional activation in mature cells,151 152 153 a mechanism that would protect these 
genes from epigenetic silencing.154 155 Gene potentiation has been linked to histone 
covalent modifications of the locus of interest. For example, a discrete site of the B-cell 
specific mouse λ5-VpreB1 locus156 157 is marked by histone H3 acetylation and lysine 4 
methylation (both marks of active chromatin) in ES cells.158 Similar observations have been 
made at the human β- (huβ-) globin locus (see below) and at the murine MHC class II locus 
in multipotent HPCs (Figure 10). According to our recent data, the murine MHC class II 
locus appears to be potentiated in bone marrow derived common lymphoid progenitor cells 
(CLP; Lin-, IL-7R+). More specifically, we assessed histone covalent modifications at 
DNaseI hypersensitive site 1 and 2 (HS1 and HS2), two of the five HSs forming the MHC 
class II LCR located 5' to the Eα gene. Our results indicate the presence of histone H3 
acetylation and lysine 4 (K4) methylation at these regions, suggesting an accessible 
chromatin conformation and potentiation of the Eα gene locus. 
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Figure 10- Chromatin immunoprecipitation (ChIP) assays on Mac-1+, B220+, and common 
lymphoid progenitor (CLP) cells. Immunoprecipitated and unbound chromatin samples were subjected to 
real-time PCR with primer set specific for the murine MHC class II locus (EαHS1 and EαHS2) and with 
another primer set specific for mouse THP (kidney-specific Tamm-Horsfall gene) promoter; pax6 (neural-
specific paired box protein 6 gene) promoter is used as a control for ChIP procedure. The level of enrichment 
(according to the 2∆∆Ct method) of globin regions relative to pax6 and input is shown by bars, with their 
corresponding standard deviations. A value of 1 indicates no enrichment. AcH3: anti-acetylated histone H3; 
K4me: anti-lysine 4 methylated histone H3; CLP: common lymphoid progenitor cells (Lin-, IL-7R+). Further 
technical details are found in ref. 159.  
As mentioned above, the development of more sensitive and accurate techniques has 
revealed that gene promoters and LCR or LCR-like structures are frequently occupied by 
lineage-specific TFs in multipotent HPCs. Recently, Anguita and collaborators160 
demonstrated that in a multipotent hematopoietic progenitor cell line, activation of the 
murine α- globin locus is associated with histone acetylation and with recruitment of 
GATA-2, NF-E2, and TAL-1 to a LCR-like structure located upstream of the genes (HS-26 
and HS-12). Despite the active chromatin conformation and TF recruitment, gene 
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expression only commences in differentiated erythroid cells, and corresponds to Pol II 
(RNA Polymerase II) recruitment to gene promoters. Chromatin activation and TF 
recruitment in primary multipotent HPCs occur in a similar way at the huβ-globin locus, 
even though in these cells TFs and cofactors are recruited at human β LCR (βLCR) as well 
as gene promoters, and gene potentiation is associated to basal level of globin gene 
expression (see below).161 Another example of potentiation and priming in multipotent 
HPCs is the lysozyme locus, where lineage-specific chromatin alterations can be detected 
prior to lysozyme transcriptional activation and cell lineage specification in multipotent 
HPCs.162 Additionally, chromatin reorganization163 and transient interactions with lineage-
specific TFs at specific lysozyme regulatory regions have been demonstrated in a 
multipotent myeloid progenitor cell line.164 
β-GLOBIN GENE POTENTIATION: THE ROLE OF LINEAGE-SPECIFIC TFs  
The huβ-globin locus consists of five developmentally regulated genes (ε-Gγ-Aγ-δ-
β).165 Their high-level expression in mature erythroid cells depends on the βLCR comprised 
of five DNaseI HSs. As expected, HS core regions are rich in hematopoietic and erythroid-
specific TF binding sites. In erythroid cells, the βLCR activates transcription through direct 
interaction with gene promoters and it is a major determinant of locus chromatin 
conformation.166 167 The β-globin locus has been extensively used as a model to investigate 
gene regulation in mature erythroid cells. More recently, it has been exploited to understand 
the mechanisms regulating gene potentiation and priming in multipotent HPCs and during 
their differentiation towards the erythroid pathway. The first report of globin potentiation 
dates back to 1992, when Jimenez and collaborators168 demonstrated that the mouse β-
globin LCR is in an open chromatin conformation in murine multilineage progenitor cell 
lines. Few years later β-like globin genes were shown to be expressed at low levels in 
hematopoietic progenitor cell lines169 and in primary HPCs of the aorta-gonad-mesonephros 
region (AGM).170 
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In an attempt to define the mechanisms leading to gene potentiation, we have 
studied globin potentiation and priming in primary multipotent HPCs of human (CD34+ 
cells) and murine (c-Kit+/CD31high/Ly-6C- cells) origin. The latter are cells purified from 
hematopoietic tissues of a mouse line transgenic for the whole huβ-globin locus (ln2). 
These transgenic mice express the huβ-like globin genes in a developmentally regulated 
manner.171 We demonstrated that in human and transgenic primary multipotent HPCs the 
globin locus is in an active chromatin conformation characterized by histone H3 
hyperacetylation and K4 dimethylation. Furthermore, we observed that chromatin 
activation is established and maintained by gene- and developmental-specific patterns of 
histone covalent modifications.172 These observations suggest that huβ-like globin genes 
are independently potentiated in HPCs, presumably through histone modifying activities 
recruited at specific regulatory regions by lineage-specific TFs. At the time we felt that 
GATA-1 and NF-E2 were good candidates because they: (1) are erythroid-specific TFs that 
interact with CBP at the locus;173 174 and (2) are expressed at low level in HPCs.175 176 Low 
level expression of lineage-specific TFs in HPCs is known as promiscuous expression since 
it initially appeared that it did not exert any precise role in HPCs.177 However, recent 
observations have led to revisit the role of lineage-specific TFs expressed at low or basal 
level in HPCs. We have demonstrated that NF-E2, in addition to stabilize CBP binding to 
the locus in erythroid cells, also plays a pivotal role in globin gene potentiation and priming 
in HPCs, since CBP recruitment to the huβ-gene promoter is NF-E2-dependent. The 
erythroid-specific factor EKLF also influences CBP binding to the locus in HPCs, most 
likely by providing an open chromatin configuration that would support NF-E2 and CBP 
recruitment. Indeed, EKLF is expressed at low levels in HPCs178 179 and, as in erythroid 
cells, it can interact with BRG1 in the E-RC1 remodeling complex targeting BRG1 to the 
locus.180 181 Accordingly, in HPCs purified from 13.5 dpc (day post coitus) EKLF knockout 
fetal livers chromatin at and huβ-promoter is not in an active conformation.182 These 
results, obtained through a genetic approach, have been confirmed by direct ChIP analysis 
using antibodies against EKLF (generous gift of S. Philipsen). As shown in Figure 11, 
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EKLF is efficiently detected at HS2 and HS3 and to the huβ-gene promoter in transgenic 
(c-Kit+/CD31high/Ly-6C- cells) as well as human CD34+ multipotent HPCs (supplementary 
section).  
 
Figure 11- Chromatin immunoprecipitation (ChIP) assays on common myeloidprogenitor 
(CMP), wild type erythroid (EryC), and EKLF knock-out erythroid (EKLF KO) cells. 
Immunoprecipitated (with antibodies against EKLF, gift of J. Philipsen) and unbound chromatin samples 
were subjected to real-time PCR with primer set specific for the huβ-globin locus (HS3, HS2, huγ- and huβ-
promoters) and with another primer set specific for mouse THP (kidney-specific Tamm-Horsfall gene) gene 
promoter; GAPDH promoter is used as a control for ChIP procedure. The level of enrichment (according to 
the 2∆∆Ct method) of globin regions relative to THP and input is shown by bars, with their corresponding 
standard deviations. A value of 1 indicates no enrichment. CMP: common myeloid progenitor cells (c-
Kit+/CD31high/Ly-6C- cells). Further technical details are found in ref. 183. 
Altogether, we propose that EKLF is instrumental in huβ-gene potentiation in 
HPCs. EKLF and BRG1 would promote chromatin remodeling and favors the association 
of other TFs (such as NF-E2) as well as cofactors (such as CBP) to the globin locus in 
HPCs. Finally, we have shown that huβ-like globin priming is associated with TBP and Pol 
II recruitment to and to TBP recruitment to huβ-gene promoter in HPCs.184 Pol II could not 
be detected at the huβ-gene promoter even though the huβ-gene is primed in HPCs. This 
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suggests that Pol II loading at the huβ-promoter is not very efficient in HPCs and it is likely 
to be the limiting step for high-level globin gene expression such as observed in erythroid 
cells (Figure 12). 
 
Figure 12- Model of TFs recruitment at the huβ-globin locus in HPCs and EryCs. Schematic 
representation of TF network at βLCR HS2 and huβ-promoter in hematopoietic progenitor cells (HPCs) and 
erythroid cells (EryCs), according to our most recent works. Huβ-gene potentiation in 13.5 dpc fetal liver-
derived HPCs is associated to NF-E2, EKLF, CBP and BRG1 recruitment to HS2. CBP and BRG1 targeting 
to HS2 occurs by, thus far, unidentified TFs (indicated by questions marks in the model). NF-E2-CBP and 
EKLF-BRG1 are also recruited at huβ-promoter, together with TBP, whereas Pol II is detected at HS2 but not 
at huβ-promoter. In EryC, looping out of intervening chromatin allows HS2 (along with βLCR holocomplex) 
and huβ-globin promoter to come in close proximity.185 The E-RC1 complex (constituted by EKLF, BRG1 
and other SWI/SNF subunits)186 farther increase chromatin remodeling at both regulatory regions and 
facilitate the recruitment of other TFs, like GATA-1.Concomitantly, Pol II, transferred from HS2 to huβ-
promoter, is efficiently phosphorylated at its C-terminal domain (CTD). Altogether, chromatin remodeling, 
histone acetylation, and phospho-CTD Pol II recruitment contribute to high-level huβ-gene transcription in 
mature EryCs. 
 67 
 
β-GLOBIN GENE POTENTIATION: THE ROLE OF LCR-LIKE 
STRUCTURES 
Analysis of several loci where gene expression is regulated by LCR or LCR-like 
structures revealed that most of them are potentiated during early hematopoietic 
development. General (GTFs) and lineage specific TFs are often bound to LCRs and gene 
promoters in multipotent HPCs, and as already discussed, some of them have been shown 
to recruit cofactors involved in chromatin remodeling or histone covalent modifications. 
This activating mechanism could counterbalance epigenetic silencing therefore allowing a 
particular locus to be maintained active from HPCs (and probably HSCs) to committed and 
differentiated hematopoietic cells. Furthermore, probably due to high density of TFs 
binding sites, LCRs can behave as nucleation centre for assembly of the preinitiation 
complex (PIC) in order to promote lineage-specific gene potentiation in HPCs and then 
high-level gene expression in mature cells.187 188 189 190 
Investigations made at the β-globin locus support these views since it has been 
observed that in HPCs the βLCR is capable of recruiting not only GTFs and Pol II191 192 but 
also lineage-specific TFs and chromatin modifying activities.193 Previous data from our lab 
led us to hypothesize that the βLCR is involved in globin gene potentiation in multipotent 
HPCs.194 To validate this hypothesis, we have investigated and compared gene potentiation 
and chromatin activation of the huβ-globin locus in HPCs purified from transgenic mice 
made either with a wild type huβ-globin locus or with a locus deleted for LCR HS2.195  
Mature erythroid cells isolated from adult hematopoietic tissues of 2B mouse line 
(containing the huβ-globin locus with a crippled LCR) display PEV (position effect 
variegation) and only one out of four erythroid cells expresses the huβ-gene even though at 
normal, high-levels.196 Since lack of HS2 significantly affects globin gene potentiation and 
priming,197 it is highly probable that βLCR dictates general chromatin conformation of the 
locus and functions as an anchoring structure for GTFs, TFs, and coactivators in HPCs. 
However, besides the important role of βLCR, we demonstrated that globin promoters are 
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also critical for gene potentiation and priming in HPCs. In actual fact, in multipotent HPCs, 
some GTFs and lineage-specific TFs are recruited to globin gene promoters according to 
their developmental activation (huβ-like globin gene expression is finely regulated during 
development; particularly γ-globin genes are expressed in fetal life and the β-gene is 
expressed in adult life).198 For example, in adult multipotent HPCs EKLF acts as a gene- 
and developmental-specific TF since it contributes to huβ- but not to huγ-gene 
potentiation.199 In conclusion, it can be assumed that both βLCR and globin gene promoters 
contribute to gene potentiation in multipotent HPCs. The βLCR would provide a chromatin 
environment prone to gene transcription and refractory to epigenetic silencing, and it would 
facilitate PIC nucleation. On the other hand, promoter regions would rather control 
developmental-specific potentiation and gene transcriptional activation (Figure 13). 
CONCLUDING REMARKS 
Molecular and biochemical studies have demonstrated that lineage-specific TFs, 
even when expressed at basal levels in HSCs or multipotent HPCs, can bind to gene 
regulatory regions like LCRs, LCR-like structures and gene promoters of a variety of 
hematopoietic loci. From the very early hematopoietic steps, lineage-specific TFs can 
recruit chromatin modifying and remodeling complexes to gene regulatory regions, hence 
favoring the recruitment of GTFs and PIC assembly. Therefore, by potentiating lineage-
specific gene expression, lineage-specific TFs can influence the identity of progeny cells. 
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Supplementary section 
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Human HPCs population (CD34+ cells) was purified and enriched from human 
leukapheresis samples by magnetic positive selection procedure. The phenotypic purity of 
enriched population was assessed by flow cytometry in FACScan when the magnetically 
selected CD34+ cells were stained with anti-CD34 (FITC)-conjugated Abs. The isolated 
population was ≥ 96% pure for CD34+ cells. Experimental details are depicted in Figure-16 
in chapter two of results section. 
As shown in Figure 11, EKLF is efficiently detected at HS2 and HS3 and to the 
human β-gene promoter in transgenic (c-Kit+/CD31high/Ly-6C- cells) as well as human 
CD34+ multipotent HPCs (Figure 13). 
 
Figure 13- Chromatin immunoprecipitation (ChIP) assays on human CD34+ multipotent HPCs 
cells. Immunoprecipitated (with antibodies against EKLF, gift of J. Philipsen) and unbound chromatin 
samples were subjected to real-time PCR with primer set specific for the human β-globin locus (HS3, HS2, 
human γ- and β-promoters) and with another primer set specific for human PAX6 (Paired box gene 6) gene 
promoter; p21 (Cyclin-dependent kinase inhibitor 1A, also known as CDKN1A) gene promoter is used as a 
control for ChIP procedure. The level of enrichment (according to the 2∆∆Ct method) of globin regions relative 
to PAX6 and input is shown by bars, with their corresponding standard deviations. A value of 1 indicates no 
enrichment. Each value is the mean ± SD of at least three independent experiments. 
 71 
 
 
 
 
 
 
Chapter two 
The basic helix-loop-helix transcription factors E2A and 
HEB are involved in globin gene expression 
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The animal modeling provides a powerful tool to directly investigate the role of 
bHLH proteins in the expression of globin genes. We tested the recruitment of bHLH 
proteins to both LCR and promoters of γ- and β-genes during the development from HPC to 
erythroid cells and investigate their recruitment considering their interaction with two 
closely related factors of ETO-2 and HDAC-1. Using the power of mouse genetics, we also 
investigated the effects of absence of E2A and HEB on the recruitment of these factors to 
β-globin locus. 
Identification of factors bound to the human β-globin locus in erythroid cells 
and murine HPCs 
Murine erythroid cells were isolated from bone marrow of adult mice transgenic for 
the entire human β-globin locus (ln2) using Ter119 antibody. Ter-119 antibody recognizes 
an epitope on murine erythroid cells at different stages of development, from early 
proerythroblasts to mature erythrocytes. These cells account for 20-25% of adult bone 
marrow cells (Figure 14.A) and do not express myeloid or B-cell markers and do not 
include more developed cells such as BFU-E or CFU-E according to colony assays.200 The 
purity of sorted population was always ≥ 95% (Figure 14.B). Murine HPCs were isolated 
from bone marrow of adult ln2 mice using Ly-6C/CD31/c-Kit antibodies. Ly-6C-
CD31highc-Kit+ cells sorted by FACS Vantage Flow Cytometer/Cell Sorter machine were 
cultured onto methylcellulose-based MethoCult® M3434 medium for colony-forming cell 
(CFC) assays to detect and quantify mouse hematopoietic progenitors in bone marrow. 
Single cultures contained 50, 100, or 200 Ly-6C-CD31highc-Kit+. Hematopoietic colony 
types were determined and scored by inverted microscope at three days, for CFU-E and at 
14 days, for BFU-E, CFU-G, CFU-GEMM, after the cultures were initiated (Table-3). 
Phenotypic characteristics of these cells are described previously. These cells (Ly-6C-
CD31highc-Kit+) include about 2% of adult bone marrow cells and are early hematopoietic 
cells without mature or late-committed properties (Figure 14.C). The purity of sorted 
population was always ≥ 95% (Figure 14.D). 
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Figure 14- Analysis of hematopoietic cells from ln2 bone marrow mice with Ter119 and Ly-
6C/CD31/c-Kit expression. Cells were stained with anti-Ter119 and anti-Ly-6C/CD31/c-Kit antibodies and 
sorted by FACS Vantage Flow Cytometer/Cell Sorter machine. Results for representative histograms obtained 
from (A) murine erythroid cells subpopulation (Ter119+), representing 20-25% of total bone marrow, and (C) 
murine HPCs subpopulation (Ly-6C-CD31highc-Kit+), representing 2% of total bone marrow. Assessment of 
phenotypic purity of (B) isolated Ter119+ fraction after sorting, and of (D) isolated Ly-6C-CD31highc-Kit+ 
fraction after sorting. Numbers indicate the percentage of the total cells localized in the indicated quadrants. 
To determine if E2A and HEB are directly involved in regulating the β-globin locus, 
chromatin immunoprecipitation was performed on chromatin prepared from erythroid cells 
and murine HPCs harvested from bone marrow of adult transgenic mice ln2. ChIP primers 
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were designed to amplify the HS3, HS2 core regions and promoters of γ- and β-globin 
genes. As aforementioned,  HS2 and HS3 regions as well as promoters of γ- and β-globin 
genes are crucial cis elements regulating the expression of globin genes which theoretically 
have potential binding sites (E-box) for E2A and HEB. The specificity of antibodies used 
against E2A and HEB were initially validated in western blot analysis prior to ChIP 
experiments (Figure 15.A). In both EryC cells and murine HPCs, strong binding of the E2A 
and HEB to HS3, and particularly to HS2 and β-promoter was observed, which were not 
affected by differentiation from HPCs to EryC cells (Figure 15.B). The patterns of 
recruitment were suggesting an increased recruitment of E2A in HPCs and an increased 
recruitm,ent of HEB in erythroid cells. E2A and HEB binding was not detectable in a 
comparable site at γ-globin promoter at regions amplified where potential binding site of 
E2A and HEB (E-box) have been described. ChIP analysis of EryCs and murine HPCs 
suggests that basal level of β-globin expression in progenitor cells and high level of β-
globin expression in EryCs could be mediated through recruitment of E2A and HEB.  
To test the hypothesis that the binding of E2A and HEB on globin locus at different 
stages of differentiation is associated with ETO-2 and HDAC-1 co-factors, we looked at the 
recruitment patterns at the same crucial regulatory regions of β-globin locus by ChIP assays 
using anit-ETO-2 and anti-HDAC-1 antibodies. The specificity of antibodies used against 
ETO-2 and HDAC-1 were initially validated in western blot analysis prior to ChIP 
experiments (Figure 15.A). In EryCs, HS3 and HS2 regions and the promoter of β-globin 
gene were identified as positive for both ETO-2 and HDAC-1 binding by ChIP (Figure 
15.C). ChIP results showed a marked binding affinity of ETO-2 to β-promoter in HPCs in 
parallel with reduction in binding in erythroid cells. HDAC-1 was more or less evenly 
recruited to HS3, HS2 and β-promoter in both EryC cells and HPCs. HDAC-1 was also 
recruited concurrently onto the γ-promoter, but the binding was weak. These findings 
suggest that ETO-2 was significantly associated with the β-promoter in progenitor cells and 
thus repressed the activity of the β-promoter by recruiting transcription repressor HDAC-1.  
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Figure 15- Chromatin immunoprecipitation (ChIP) assays on murine erythroid cells (EryC, 
Ter119+) and murine hematopoietic progenitor cells (HPC, Ly-6C-CD31highc-Kit+). (A) Western blot 
analysis of cell lysates from 12.5 dpc fetal liver ln2 wild type cells expressing E2A (90kDa), HEB (85kDa), 
ETO-2 (76kDa) and HDAC-1 (55kDa) proteins. Immunoprecipitated with antibodies against (B) E2A and 
HEB or (C) ETO-2 and HDAC-1, and unbound chromatin samples were subjected to real-time PCR with 
primer sets specific for the human β-globin locus (HS3, HS2, huγ- and human β-promoters) and with another 
primer set specific for mouse THP (kidney-specific Tamm-Horsfall gene) gene promoter; GAPDH promoter 
is used as a control for ChIP procedure. The level of enrichment (according to the 2∆∆Ct method)201 of globin 
regions relative to THP and input is shown by bars, with their corresponding standard deviations. A value of 1 
indicates no enrichment. Each value is the mean ± SD of at least three independent experiments.  
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Identification of factors bound to the human β-globin locus in human primitive 
progenitor cells 
Human primitive progenitor cells express CD34 (Cluster of Differentiation 34) and 
represent 1-3% of total human bone morrow cells. Colony-forming assays have shown that 
this population includes all bi or unipotent, colony forming units-granulocyte-macrophage 
(CFU-GM), CFU megakaryocyte (CFU-meg), burst forming units-erythroid (BFU-E) and 
multipotent progenitors CFU granulocyte/erythroid/macrophage/megakaryocyte (CFU-
GEMM) as well as pre-CFU.202 Although several CD34 antibodies are commercially 
available to isolate CD34+ cells from human bone morrow, it is lengthy to separate the 1-
3% CD34+ cells on the scale required for Chromatin Immunoprecipitation. A simple and 
rapid method to isolate primitive hematopoietic progenitor cells from bone marrow is to use 
immunomagnetic cell selection procedure. To enrich for human HPCs, CD34+ cells were 
purified from human leukapheresis samples by magnetic positive selection procedure 
(Figure 16.A). The phenotypic purity of enriched population (Figure 16.B) was assessed by 
flow cytometry in FACScan when the magnetically selected CD34+ cells were stained with 
anti-CD34 (FITC)-conjugated Abs (Figure 16.C). The isolated population was ≥ 96% pure 
for CD34+ cells (Figure 16.D). 
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Figure 16- Purification of human hematopoietic progenitor cells (CD34+). (A) Schematic 
representation of magnetic positive selection procedure. Bone marrow CD34+ cells (B, Left), Bone marrow 
CD34 carrying cells and magnetic beads (B, Right). Flow cytometric analysis of magnetic selected cells (C, 
Left), CD34+ subpopulation representing about 2% of total bone marrow (C, Right). Assessment of 
phenotypic purity of CD34+ isolated fraction. Numbers indicate the percentage of the total cells localized in 
the indicated quadrants. 
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In the comparative ChIP experiments on human HPCs, harvested from human 
leukapheresis samples (hereafter referred to as bone marrow cells), binding of the E2A and 
HEB to HS3, and particularly to HS2 and β-promoter was observed (Figure 17.A and B), 
and their patterns of association were similar. E2A and HEB were also associated with the 
γ-promoters. We carried out ChIP analyses for ETO-2 and found that ETO-2 is 
significantly recruited to the LCR and β-promoter but not to γ-promoters (Figure 17.C). 
These findings are explained seeing that CD34+ cells were purified from leukapheresis 
samples and the patients received stem cell factor (SCF) and granulocyte colony-
stimulating factor (G-CSF) treatment to increase CD34+ cell mobilization. The addition of 
SCF to G-CSF remarkably enhances the mobilisation of peripheral blood progenitor 
cells.203 SCF can also induce γ-globin expression in adult human erythroblasts.204 The same 
finding was observed in terms of EKLF recruitment to γ-promoter in human CD34+ cells 
(Chapter 1, Figure 12). ETO-2 binding pattern is consistent with the low level of β-globin 
gene expression in primitive progenitor cells and the expected effect of ETO-2 as a 
repressor of transcription.205,206 Using ChIP assays, we similarly demonstrated the presence 
of HDAC-1 at the LCR and the γ- and β-promoter regions. As shown in Figure 17.D, all 
regulatory regions appeared to be active binding site for HDAC-1 and the binding was 
relatively alike across the locus but not at the control region (p21 promoter). 
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Figure 17- Chromatin immunoprecipitation (ChIP) assays on human CD34+ multipotent HPCs 
cells. Immunoprecipitated with antibodies against (A) E2A, (B) HEB, (C) ETO-2 and (D) HDAC-1 and 
unbound chromatin samples were subjected to real-time PCR with primer sets specific for the human β-globin 
locus (HS3, HS2, human γ- and β-promoters) and with another primer set specific for human PAX6 (Paired 
box gene 6) gene promoter; p21 (Cyclin-dependent kinase inhibitor 1A, also known as CDKN1A) gene 
promoter is used as a control for ChIP procedure. The level of enrichment (according to the 2∆∆Ct method)207 
of globin regions relative to PAX6 and input is shown by bars, with their corresponding standard deviations. 
A value of 1 indicates no enrichment. Each value is the mean ± SD of at least three independent experiments. 
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Identification of factors bound to the human β-globin locus in murine 
lymphoid progenitor (LP: Lin-c-KitlowSca1lowIL-7Rα+) cells 
Adult ln2 mice were killed and murine LPs were isolated from bone marrow using 
Lin-c-KitlowSca1lowIL-7Rα+ expression profile. Lin-c-KitlowSca1low cells were initially 
isolated by negative selection magnetic system (Figure 18.A) and then stained for IL-7Rα 
and sorted by FACS Vantage Flow Cytometer/Cell Sorter machine. These cells (Lin-c-
KitlowSca1lowIL-7Rα+) include about 0.2% of adult bone marrow cells (Figure 18.B). The 
purity of sorted population was always ≥ 95% (Figure 18.C). 
 
Figure 18- Purification of murine lymphoid progenitor (LP: Lin-c-KitlowSca1lowIL-7Rα+) cells. 
(A) Schematic representation of magnetic negative selection procedure. Lin-c-KitlowSca1low cells (B, Left) 
were stained with IL-7Rα antibody and those positive for IL-7Rα were gated and sorted by FACS Vantage 
Flow Cytometer/Cell Sorter machine. This subpopulation was representing about 2% of total bone marrow 
(B, Right). (C) Assessment of phenotypic purity of IL-7Rα + isolated fraction. Numbers indicate the 
percentage of the total cells localized in the indicated quadrants. 
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The lymphoid developmental potential of enriched LP pop of cells from bone 
marrow and the sorted LP population were determined in long term bone marrow culture 
(LTBMC) according to Whitlock-White (W-W) culture system (Figure 19). W-W culture is 
an established in vitro model system specific for the lymphoid-lineage hemopoiesis.208 The 
cultured cells were fed by the removal of the growth medium and replenishment with the 
fresh medium. Colonies were counted 3 weeks after the incubation. The myeloid-specific 
differentiation potential of murine HPCs was also verified by Whitlock-Witte culture 
system. The ratio of LP cells/Total Bone Marrow was calculated by limiting dilutions using 
the LDA program. We observed a linear relationship between the number of cells plated 
and the number of B-cell colonies obtained, with an average of 1 LP/5000 MNC (Table-3). 
As expected, LP cells did not show any erythro-myeloid activity evidenced by no growth in 
complete methylcellulose-based M3434 medium, and HPCs did not yield any cell with 
lymphoid-lineage potential in W-W culture system vice versa.  
 
Figure 19- Whitlock-Witte long-term bone marrow culture. Bone marrow cells from adult mice 
were extracted and plated on a fresh monolayer of S17 stromal cells. B-cell colonies were scored at day 21.  
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 Colonies/103 cells Colonies/103 cells 
 M3434 culture Whitlock-Witte assay 
HPC: Ly-6C-CD31highc-Kit+ 220 ± 25 0 
LP:Lin-c-KitlowSca1lowIL-7Rα+ 0 ND 
 Colonies/104 cells Colonies/104 cells 
Total Bone Marrow 41 ± 8 3.75 ± 1.2 
 
Table 3- The ratio of LP (lymphoid progenitor) cells/Total Bone Marrow was calculated by 
limiting dilutions using the LDA program. We observed a linear relationship between the number of cells 
plated and the number of B-cell colonies obtained, with an average of 1 LP/5000 MNC. As expected, LP cells 
did not show any erythro-myeloid activity evidenced by no growth in complete methylcellulose-based 
MethoCult M3434 medium by performing colony-forming cell (CFC) assays. Similarly, HPCs did not yield 
any cell with lymphoid-lineage potential in Whitlock-Witte culture system. 
Histone H3 acetylation (H3Ac) at the lysine-9 and -14 (K9) are well-established 
markers of active chromatin and presumably leads to the formation of a chromatin 
environment that promotes the accessibility of promoters to transcription factors and thus 
the transcription.209 We tested the hypothesis that β-globin locus is in active chromatin in 
LP cells that is manifested as increased histone acetylation at the K9 and k14 residues of 
the H3 histone associated with the LCR and γ- and β-promoters. Using ChIP assay, we 
studied the pattern of histone acetylation at the β-globin locus and showed for the first time 
that β-globin locus is in active chromatin configuration in LP cells evidenced by 
enrichment of H3Ac at LCR (HS3 and HS2) and γ- and β-promoters with a trend toward 
greater acetylation at HS2 and β-promoter (Figure 20.A). To determine if histone 
acetylation of β-globin locus is associated with increased interaction between transcription 
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factors and the regulatory regions, we performed ChIP analysis for E2A and HEB. Our data 
indicated that the chromatin acetylation status correlated with the binding of E2A (Figure 
20.B). The HS3, HS2 and β-promoter interacted mainly with E2A though minimal binding 
of HEB was also seen at LCR (HS3, HS2) (Figure 20.C). γ-promoters was also found to be 
positive for E2A (Figure 20.B). These results suggest the basal level of β-globin expression 
in LP cells is mediated by recruitment of E2A and minimal binding of HEB. Since ETO-2 
binding mediates the repressive effect, we examined the interaction of ETO-2 with the LCR 
and γ- and β-promoters using ChIP assay. All the regulatory regions exhibited high level of 
binding for ETO-2 (Figure 20.D). Thus the presence of ETO-2 could prevent high level of 
globin gene expression in LP cells. To obtain some more information, mRNA expression of 
human β-globin gene was determined by RT-PCR of total RNA obtained from LP cells and 
data was calculated as relative expression to HPCs (HPC/LP: 15X) and to erythroid cells 
(EryC/LP: 2400X). Taking all together, our findings suggest that human β-globin is in 
active chromatin in LPs characterized by H3Ac binding according to ChIP assays and basal 
level of expression according to RT-PCR results. 
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Figure 20- ChIP analysis of histone acetylation and interaction of E2A, HEB and ETO-2 
proteins with the human β-globin locus in LP (Lin-c-KitlowSca1lowIL-7Rα+) cells from adult ln2 mice. 
(A) Acetyl-histone H3 profiling of globin gene locus was assayed using ChIP. Immunoprecipitated chromatin 
with antibodies against (A) Acetyl-histone H3, (B) E2A, (C) HEB or (D) ETO-2, and unbound chromatin 
samples were subjected to real-time PCR with primer set specific for the human β-globin locus (HS3, HS2, 
human γ- and β-promoters) and with another primer set specific for mouse THP (kidney-specific Tamm-
Horsfall gene) gene promoter. The silent Amylase promoter was used as a negative control and to set the 
baseline of one-fold enrichment. The level of enrichment (according to the 2∆∆Ct method)210 of globin regions 
relative to THP and input is shown by bars, with their corresponding standard deviations. A value of 1 
indicates no enrichment. Each value is the mean ± SD of at least three independent experiments. 
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Identification of factors bound to the human β-globin locus in fetal erythroid 
cells with E2A and HEB knock-out background 
Novel mouse models knock-out for E2A and HEB and transgenic for human β-
globin locus were generated after a long process of breeding of homozygous mutant mice 
for E2A and HEB (E2A +/- and HEB +/-) with males or females of ln2 +/+ background, 
respectively (Figure 21.H). As described above, E2A knockout (E2A-/-) and HEB knockout 
(HEB -/-) genotypes are almost always lethal before birth;211 therefore, hematopietic cells 
from E2A-and HEB-null backgrounds were harvested from fetal livers of 13.5 dpc 
embryos. All genotypes were confirmed by polymerase chain reaction. Representative PCR 
analyses of genomic DNA prepared from fraction of these cells and their corresponding 
PCR products are shown in Figure 9. All animals were maintained under specific-pathogen-
free conditions. 
Fetal liver erythroid cells (FL EryC 13.5 dpc) with E2A-/- ln2+ or HEB-/- ln2+ 
genotype were subjected to ChIP assays, in separate experiments, to investigate the effect 
of absence of either E2A or HEB on recruitment of other factors to β-globin locus. The 
alteration of transcriptional network at globin locus in erythroid cells and the possibility of 
compensatory factors, when E2A and HEB proteins are absent, can be investigated by such 
knock-out studies. ChIP samples from knock-out and wild-type backgrounds were prepared 
in simultaneous parallel experiments for each protein. As expected, both E2A and HEB 
were first detected at the regulatory regions, LCR and β-promoter, of β-globin locus in 
wild-type background (Figure 21.A and D). The pattern of recruitment was similar to and 
so confirmatory the data found in terms of erythroid cells (Ter119+) in normal ln2 
background. Neither E2A nor HEB was bound to γ-promoters in wild-type fetal liver 
erythroid cells (Figure 21.A and D). Similar enrichments were observed as high level of 
ETO-2 binding at both the LCR and β-promoter and also as minimal binding thereof at γ-
promoters (Figure 21.B and E). Generally, in both knock-outs, a slight increase in binding 
potential was observed for all factors when the ChIP results of knock-out backgrounds were 
 86 
 
compared to those obtained from wild-type. That is, when ChIPs performed with HEB 
antibody on E2A-knouck-out FL EryCs and also when ChIPs performed with E2A 
antibody on HEB-knock-out FL EryCs, the higher level of enrichment was detected (Figure 
21.A and D). In addition, γ-promoters were found to be positive for both E2A and HEB in 
knock-out backgrounds (Figure 21.A and D). Further to such findings, one may argue that 
the recruitment of any of these two factors was either entirely independent of the presence 
of another indicating that their recruitment was not a reflection of the expression levels of 
the other and thus suggesting the existence of different protein complex at β-globin locus, 
or  they can have repressor activity independently. This increase in enrichment was more 
obvious in case of ChIP assays with anti-ETO-2 in both E2A and HEB knockouts (Figure 
21.A and D). When it came to ChIP assays for HDAC-1 protein, a lower level of HDAC-1 
enrichment was evenly detected at the LCR and β-promoter in wild-type and knock-outs of 
both E2A and HEB (Figure 21.C and F). Moreover, the γ-promoters were identified as 
negative for HDAC-1 recruitment in both E2A and HEB knock-outs (Figure 21.C and F).  
The E2A and HEB recruitment could not be detected by immunoprecipitation with 
related antibodies in corresponding knock-out background (Figure 21G), confirming the 
specificity of the antibodies used in the ChIP assays and genotypes of extracted fetal liver 
cells and the accuracy of ChIP experiments.  
 
 
 87 
 
 
Figure 21- ChIP assays on fetal liver eythroid cells (13.5 dpc) with wild-type and knock-out 
backgrounds. Immunoprecipitated chromatin with antibodies against (A) HEB, (B, E) ETO-2, (C, F) HDAC-
1 or (D) E2A, and unbound chromatin samples either in E2A knock-out erythroid cells (A, B and C) or in 
HEB knock-out erythroid cells (D, E, F) were subjected to real-time PCR with primer sets specific for the 
human β-globin locus (HS3, HS2, human γ- and β-promoters) and with another primer set specific for mouse 
THP (kidney-specific Tamm-Horsfall gene) gene promoter. The similar assays were performed using 
antibodies against the knock-out proteins to control the ChIP experiments (G). The silent Amylase promoter 
was used as a negative control and to set the baseline of one-fold enrichment. The level of enrichment 
(according to the 2∆∆Ct method)212 of globin regions relative to THP and input is shown by bars, with their 
corresponding standard deviations. A value of 1 indicates no enrichment. Each value is the mean ± SD of at 
least three independent experiments. (H) Schematic diagram of generation and establishment of knock-out 
mouse models used in study and representative PCR analysis of genotype (see methods and Figure 9). 
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The combination of chromatin immunoprecipitation (ChIP) assay with real-time 
PCR has provided a major boost to quantitatively measure the relative interaction of 
transcription factors with endogenous chromatin sites in living cells.213 ChIP analyzing 
helps to understand how transcription factors select functional sites in the genome.214 This 
attests to the intense interest in the field globin research and the acknowledgement of the 
potential for animal modeling to advance understanding in this area. We utilized the power 
of mouse genetics to propose incisive information about the transcriptional control of β-
globin locus during hematopoiesis. Animal model of human β-globin locus, namely Ln2, is 
a widely accepted and well established model to investigate the molecular events regulating 
the β-globin locus during erytropoiesis.215,216  
Understanding the in vivo function of the LCR and promoters will enrich our 
knowledge about the process of gene activation. While research on globin has shown a 
surge in popularity, no group has yet approached the crucial issue of the mechanisms by 
which E proteins regulate β-globin gene expression in vivo. In this respect, our results 
provide the first evidence to date to support the hypothesis that the E proteins E2A and 
HEB, are important transcription factors directly involved in regulating the human β-globin 
locus during hematopoietic differentiation. The present project is in a unique position to 
address these mechanisms, since we bring together data from different murine 
hematopoietic cell types containing normal human β-globin locus in combination with the 
study of knockout backgrounds. This mix is essential to fairly increase the body of 
knowledge in terms of transcriptional control of β-globin locus by E proteins. Data 
provided here could be employed in novel pharmacological approaches targeting the 
mechanisms involved in transcriptional control of β-globin gene expression and hopefully 
one would come up with new ideas for treatment of sickle cell anemia and/or β-
thalassemia.    
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Human β-globin locus in erythroid cells and murine HPCs 
ChIP experiments performed on chromatin prepared from murine erythroid cells 
and HPCs, harvested from transgenic mouse ln2, showed the strong binding of the E2A and 
HEB to HS3, and particularly to HS2 and β-promoter in both murine HPCs and EryC cells. 
The patterns of binding were roughly not affected by differentiation from HPCs to EryC 
cells suggesting that the recruitment of E2A and HEB per say is not modulating the 
transcription level of b-like globin genes during erythropoiesis. However, the pattern of 
recruitment suggest that E2A recruitment is more pronounced in HPCs while recruitment of 
HEB is increasing from HPC to EryC. This model is consistent with the pattern of 
recruitment and with the role that E2A and HEB play in lymphoid-lineage during B-cell 
and T-cell differentiation. That is, E2A is recruited to regulatory regions of lymphoid cell-
specific genes during lymphoid-lineage priming in the multipotent progenitor population217 
and HEB is involved in T-lymphoid and B-lymphoid lineage commitment and the 
expression of lymphoid-lineage specific genes in more mature cells.218,219,220 
Our results suggest that in non-committed hematopoietic progenitor cells the LCR 
and β-globin promoter are already occupied by E2A and HEB. We also show that the 
binding of E2A and HEB to crucial regulatory regions on β-globin locus, at specific stages 
of differentiation, is associated with ETO-2 and HDAC-1 factors. A noticeable binding of 
ETO-2 to β-promoter in HPCs could explains the basal-level of β-globin gene expression 
once the activating effects of E2A and HEB are counterbalanced by ETO-2 and thus 
suggests that the previously published complex221 which contains E2A, HEB and ETO-2 
present at β-promoter in HPCs. The reduction in ETO-2 binding to β-promoter in erythroid 
cells, even if E2A and HEB are highly recruited to both, the LCR and β-promoter, is 
consequential with the high-level of β-globin gene expression to erythroid cells. HDAC-1 
was also evenly recruited to HS3, HS2 and β-promoter in both HPCs and EryC suggesting 
that the repression activity of ETO-2 in HPCs is in part due to the recruitment of the 
transcription repressor HDAC-1. The fact that E2A and HEB binding could not be detected 
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(at significant level) by ChIP assays at γ-globin promoters, further supports the activating 
role of E2A and HEB in globin gene expression since the γ-globin genes are not 
transcriptionally active in EryC at that stage of development. The potentiation of globin 
genes in hematopoietic progenitor cells is actually gene specific during development and 
fits with the subsequent  transcriptional activation of the specific globin genes.222 223  
This differentiation-coupled recruitment of E2A, HEB and ETO-2 indicates the 
harmony between their recruitment to β-globin locus and lineage- differentiation along with 
commitment. Results from our study suggest that E2A and HEB form homo- and 
heterodimers that bind to erythroid cell-specific genes.   
Human β-globin locus in human primitive progenitor cells 
Human early hematopoietic forming progenitor cells (human CD34+ cells) represent 
1-3% of total human bone morrow cells. Colony-forming assays have shown that this 
population includes all unipotent, colony units-granulocyte-macrophage (CFU-GM), CFU 
megakaryocyte (CFU-meg), burst forming units-erythroid (BFU-E) and multipotent 
progenitors CFU granulocyte/erythroid/macrophage/megakaryocyte (CFU-GEMM) as well 
as pre-CFU.224 ChIP analysis performed on human HPCs harvested from human 
leukapheresis samples showed that E2A and HEB bind to HS3, and particularly to HS2 and 
β-promoter, and seem to follow a similar pattern of recruitment. These results further 
suggest the importance of E2A and HEB in the human β-globin gene potentiation and in the 
basal level of gene expression in HPCs.  
Interestingly, we also found that E2A, HEB and also EKLF were associated with the 
γ-promoter. These findings were expected in the light of treatment of leukapheresis samples 
with stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) to increase 
CD34+ cell mobilization.225 SCF can induce γ-globin expression in adult human 
erythroblasts.226 Similarly, previous studies have reported that the reactivation of fetal 
hemoglobin (HbF, α2γ2) synthesis and erythroid cell proliferation can be achieved by 
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addition of biosynthetic GM-CSF.227 The mechanisms underlying HbF reactivation have 
not been elucidated yet, but the modification of chromatin structure of the β-like globin 
gene cluster is raised as a possible mechanism of action.228 HDAC-1 is present at all 
regulatory regions across the locus. HDACs can induce local condensation in chromatin 
through the deacetylation of the acetylated lysine residues in histone tail and block access 
of transcriptional factors.229 The histone deacetylase (HDAC) inhibitors like sodium 
butyrate (NaB) and trichostatin A (TSA) were shown to be able to maintain active 
chromatin structure at γ-globin promoter, via histone hyperacetylation, and thus maintain 
the expression of the fetal globin gene and HbF production.230,231,232 The γ-globin 
promoters may be up-regulated by binding of transcription factors evidenced herein by 
recruitment of EKLF, E2A and HEB and the absence of ETO-2 as a repressor of 
transcription. ETO-2 binding pattern to LCR and β-promoter but not to γ-promoters was 
again consistent with the low level of β-globin gene expression in early progenitor cells and 
the expected effect of GM-CSF in stimulating the promoters of γ-globin genes. These data 
recommend the pharmacologic agents able to alter the chromatin structure as attractive 
drugs to reach the clinically effective levels of HbF production and open new horizons to 
treatment of individuals with sickle cell anemia and β-thalassemia in the future.  
Human β-globin locus in murine lymphoid progenitor cells (LPs)  
We next focused on the β-globin locus in lymphoid progenitor cells (LPs) to 
investigate the epigenetic state of the promoter and an upstream control region (LCR). 
Murine LPs were isolated from adult bone marrow according to their specific cell surface 
markers (Lin-c-KitlowSca1lowIL-7Rα+).  
Histone H3 acetylation (H3Ac) at the lysine-9 (K9) is an epigenetic mark usually 
associated with active chromatin and is a characteristic of transcriptional activation in 
active genes.233 Acetylation of the histone tails disrupts histone binding to negatively 
charged DNA and thus forms an open active chromatin (euchromatin) that promotes the 
transcription factor binding, i.e. genes in open chromatin domains are prepared for 
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expression. Once the activator proteins bind to regulatory regions, transcription commences 
and high-level of gene expression is achieved. Firstly, histone modifications were analyzed 
by ChIP assays and general acetylation of H3 was observed at both the promoters of γ- and 
β-genes and LCR. By such findings, we showed for the first time that β-globin locus is in 
open chromatin configuration in lymphoid progenitor cells which is consistent with the 
basal level of expression of globin genes in lymphoid progenitors.   
There has been no previous study to directly characterize E2A and HEB binding to 
β-globin locus in lymphoid progenitor cells (LPs). In fact, the investigation of the 
chromatin organization and transcription factor recruitment at the beta-globin locus in LP 
has never been done before. The attempts were made to assess whether histone acetylation 
of β-globin locus is associated with increased interaction between transcription factors and 
the regulatory regions. There is a marked binding of E2A to regulatory regions, at both the 
LCR and promoters, across the locus. Moreover, HEB protein was found to be minimally 
present at LCR and β-promoter at a basal level. There was significant enrichment of ETO-2 
at both, the LCR and promoters that marks characteristic of repressed gene promoters. 
Thus, the β-globin gene locus may exist in an open chromatin conformation in LPs before 
terminal lymphoid differentiation, and the assemblage of functional transcription apparatus 
to the LCR and active promoters may be a lineage-specifying and rate-limiting step in 
activation of β-globin gene expression. The histone acetylation that we observed here is not 
exceptional. Previous studies have similarly shown that several active genes like interferon-
α (IFN-α)234 and hormone receptor-dependent genes235 in mammals, and PHO8 gene in 
Saccharomyces cerevisiae,236 are hypoacetylated to facilitate the recruitment of remodeling 
complexes. We conclude that histone the histone post-translational modifications and E2A 
binding to LCR and β-promoter in LPs results in a basal level of β-globin expression.  
To verify the transcriptional effects of these factors on β-globin gene expression 
following their binding to locus, we also studied the level of β-globin gene expression in 
LPs. The concentration of human β-globin gene mRNA was determined by RT-PCR of 
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total RNA obtained from LP cells and data was calculated as relative expression to HPCs 
(HPC/LP: 15X) and to erythroid cells (EryC/LP: 2400X). These results show that the H3 
acetylation and binding of E2A alone at the LCR and β-promoter is not sufficient for high 
level of transcription. This reduction of β-globin gene expression could be mediated in part 
by recruitment of ETO-2 to crucial regulatory regions. Other epigenetic mechanisms and 
repressive factors may also influence transcriptional activity and contribute to such 
decrease in expression.  
Our results suggest that the β-globin gene and promoter would first be 
epigenetically marked by histone H3 acetylation in LPs and by basal level of expression 
prior to differentiation to more mature lymphoid cells where the locus is epigenetically 
silenced by the formation of a heterochromatin structure.  
E2A and HEB are associated with lineage- differentiation and commitment  
Taken together, results of the present study suggest that a defined pattern of 
transcription factor binding is important for the specific activation of human globin 
promoters and the human globin LCR in HPCs and erythroid cells. We showed that E2A 
and HEB drive β-promoter and β-LCR activity in HPCs through their high-affinity binding 
to two important regulatory regions: LCR and β-promoter.  
Earlier in vivo studies have indicated that chromatin is in open configuration at the 
human β-globin promoters and β-LCR in HPCs. The chromatin accessibility and 
recruitment of activating transcription factors to human β-globin regulatory regions set the 
gene-specific potentiation in HPCs before erythroid-lineage commitment. Accessibility at 
HS2 and HS3 increases in mature erythroid cells comparing with HPCs.237 Herein, ChIP 
results from murine HPCs and human CD34+ cells suggest that β-globin gene-potentiation 
in HPCs are mediated in part by binding of E2A and HEB, particularly of E2A to β-LCR 
and β-promoter. During erythroid differentiation from HPCs to erythroid cells, ETO-2 
binding affinity decreases at the LCR and promoters as cells progress through the later 
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stages of erythroid differentiation. Thus, high-level of β-globin gene expression in erythroid 
cells versus basal-level of β-globin gene expression in HPCs are acquired, after further 
remodeling of LCR and β-promoter during differentiation, through binding of different 
factors and/or with different relative ratios to the same regulatory regions. The ETO-2 
counterbalances the activating effect of E2A and HEB in HPCs but not in erythroid cells. 
However, E2A and HEB alone are not sufficient and other factors are definitely required 
for an appropriate gene expression in different stages of differentiation. 
Significantly, our results suggest that the pattern of histone acetylation in LPs is 
important for the transcriptional potentiation of globin genes and, more interestingly, for 
the developmentally regulated expression of these genes in erythroid cells. We show that 
the promoters of human globin genes are epigenetically active such as evidenced by histone 
H3 acetylation in LPs and we suggest that this potentiation allows proper expression in 
terminally differentiated erythroid cells via the recruitment of activators and/or remodeling 
complexes.  
Human β-globin locus in E2A and HEB knock-out fetal erythroid cells 
Novel mouse models knock-out for E2A and HEB and transgenic for human β-
globin locus were generated in present project. Since E2A knockout (E2A-/-) and HEB 
knockout (HEB -/-) genotypes were almost always lethal,238 fetal EryC from E2A-and 
HEB-null backgrounds were harvested from fetal livers of 13.5 dpc embryos. About 80-
90% of cell population harvested from 13.5 dpc fetal liver consists of erythroid cells. No 
deviation in phenotype was detected in mice heterozygote for E2A (+/-) or HEB (+/-) or in 
13.5 dpc embryos. The knock-out study was a major advantage of this project as the 
alteration of transcriptional network at globin locus in erythroid cells and the possibility of 
compensatory factors could be investigated when E2A and HEB proteins were absent. 
ChIP assays were performed on fetal liver erythroid cells with wild-type and knock-
out (E2A-/- ln2+ or HEB-/- ln2+) backgrounds in simultaneous parallel experiments. Both 
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E2A and HEB were detected at the regulatory regions, LCR and β-promoter, on β-globin 
locus in wild-type, which further emphasized their presence as a part of transcriptional 
network involved in β-globin gene expression. These data are consistent with our findings 
in erythroid cells (Ter119+) in normal ln2 background. With similar explanation, neither 
E2A nor HEB was bound to γ-promoter in wild-type fetal liver erythroid cells while high 
level of enrichment was seen for ETO-2 at both LCR and β-promoter besides its minimal 
binding to γ-promoter.  
In both E2A and HEB knockouts, a slight increase in binding potential was 
observed for all factors when the ChIP results of knock-out backgrounds were compared to 
those obtained in wild-type. In addition, γ-promoters was found to be positive for both E2A 
and HEB in knock-out backgrounds. The absence of E2A in the knockout mice could be 
compensated by recruitment of HEB, and vice versa. The in vivo association of E2A and 
HEB to LCR and β-promoter indicates that a knockout of E2A or HEB gene does not 
inhibit the recruitment of the other. In other words, the recruitment of any of these two 
factors is independent of the presence of the other indicating that their recruitment is not a 
reflection of the expression levels of the other. 
These observations suggest that neither E2A nor HEB are the limiting factor for the 
formation and recruitment of the ETO2 containing complex sitting at the locus. E2A and 
HEB are most likely in that complex but only one of them is sufficient for the recruitment 
of this ETO-2 complex to the locus. Given the dynamic nature of these protein complexes 
and widespread nature of E protein expression, their expression levels and their relative 
ratio could fluctuate during hematopoiesis and consequently master the lineage-specific 
gene expression. One may argue that E2A and HEB proteins can be present in different, 
and at least in more than one, protein complexes at locus and therefore be targeted to 
regulatory sequences through participation in different protein complexes. Supporting this 
issue, E2A and HEB are recently demonstrated to bind to β-globin LCR and β-globin gene 
promoter during erythroid differentiation via two different protein complexes of ETO-2 and 
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TAL-1, and TAL-1, HEB and E2A protein levels have been shown to fluctuate during 
differentiation. The detachment of ETO-2 complex, evidenced by decrease in level of ETO-
2, allows the activation of late erythroid genes. Therefore, the function of E2A and HEB in 
transcription activation has been postulated through the cooperation of multiple 
transactivators. 239 
  Conclusion 
In closing, we wish to emphasize that the ability of E proteins to form different 
homo/heterodimers make them challenging to study, but our results suggest that E-protein 
are key players in the expression of β-globin gene during erythroid differentiation from 
HPCs to mature erythroid cells. The accumulation of E proteins increases at β-globin locus 
in parallel with lineage-specification and commitment. As discussed here, initially in 
triggering hematopoiesis and later at each step of differentiation, the accumulation of a 
large amount of small changes in chromatin structure and transcription factors will form a 
finely orchestrated network necessary for developmental changes. The expression of a 
variety of tissue-specific genes is potentiated in progenitor cells and the chromatin 
preserves an accessible configuration for transcriptional machinery. Gene potentiation 
appears to counterbalance epigenetic silencing of lineage-specific genes in early 
progenitors, while maintaining an accessible chromatin conformation in the lineage 
pathway selected. Our results emphasize the complementary role of locus control region 
(LCR) or LCR-like structures and promoter regions in gene-specific potentiation events. 
The interplay between ubiquitous transcription factors, lineage-specific transcription 
factors, and chromatin remodeling activities determines the outcome of transcription. In 
addition, different sets of E protein target genes could be activated at each step. A 
comprehensive understanding of how E proteins could regulate globin gene expression 
calls for more studies from a molecular standpoint.  
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